voriconazole has been researched along with Candidiasis in 311 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 7 (2.25) | 18.2507 |
| 2000's | 159 (51.13) | 29.6817 |
| 2010's | 120 (38.59) | 24.3611 |
| 2020's | 25 (8.04) | 2.80 |
| Authors | Studies |
|---|---|
| Algueró, M; Bartroli, J; Boncompte, E; Conte, L; Forn, J; García-Rafanell, J; Merlos, M; Ramis, J; Turmo, E; Vericat, ML | 2 |
| Bille, J; Bolay, S; Buclin, T; Calandra, T; Decosterd, LA; Majcherczyk, PA; Marchetti, O; Nieth, V; Pascual, A; Sanglard, D | 1 |
| Bergès, T; Bouchara, JP; Chabasse, D; Hennequin, C; Tronchin, G; Vandeputte, P | 1 |
| Cheng, S; Clancy, CJ; Derendorf, H; Li, Y; Nguyen, MH | 1 |
| Fritsche, TR; Jones, RN; Rhomberg, PR; Sader, HS | 1 |
| Hashimoto, K; Kaeriyama, M; Kimura, A; Mitsuyama, J; Narita, H; Nishikawa, H; Nomura, N; Todo, Y; Yamada, E | 1 |
| Alastruey-Izquierdo, A; Almirante, B; Cuenca-Estrella, M; Gomez-Lopez, A; Pahissa, A; Rodriguez, D; Rodriguez-Tudela, JL | 1 |
| Chapman, SW; Cleary, JD; Garcia-Effron, G; Perlin, DS | 1 |
| Jacobson, MJ; Nguyen, G; Patel, R; Piper, KE; Steckelberg, JM | 1 |
| Bergès, T; Bouchara, JP; Chabasse, D; Ernoult, E; Larcher, G; Tronchin, G; Vandeputte, P | 1 |
| Garcia-Effron, G; Kontoyiannis, DP; Lewis, RE; Perlin, DS | 1 |
| Cannon, RD; Holmes, AR; Lamping, E; Nakamura, K; Niimi, K; Niimi, M; Ranchod, A; Tyndall, JD | 1 |
| Arendrup, MC; Bruun, B; Buzina, W; Garcia-Effron, G; Jensen, HE; Lass-Flörl, C; Lundin, C; Mortensen, KL; Perlin, DS; Reiter, N | 1 |
| Dimopoulos, G; Falagas, ME; Velegraki, A | 1 |
| Guarro, J; Mariné, M; Pastor, FJ; Serena, C | 1 |
| Kang, CI; Mandrekar, JN; Patel, R; Rouse, MS; Steckelberg, JM | 1 |
| Chapeland-Leclerc, F; Girard, A; Hennequin, C; Lacroix, C; Noël, T; Papon, N; Ribaud, P; Socié, G | 1 |
| Coste, A; Ischer, F; Jacobsen, MD; MacCallum, DM; Odds, FC; Sanglard, D | 1 |
| Inamine, T; Izumikawa, K; Kakeya, H; Kohno, S; Miyazaki, T; Miyazaki, Y; Nagayoshi, Y; Saijo, T; Seki, M; Yamamoto, Y; Yamauchi, S; Yanagihara, K | 1 |
| Garneau-Tsodikova, S; Garzan, A; Shrestha, SK | 1 |
| Gazzola, S; Guillon, R; Le Pape, P; Logé, C; Montoir, D; Ourliac-Garnier, I; Pagniez, F; Picot, C; Planchat, A; Soklou, KE; Tonnerre, A | 1 |
| Han, G; Li, C; Li, Z; Liu, N; Sheng, C; Tu, J | 1 |
| Atiencia-Carrera, MB; Cabezas-Mera, FS; Machado, A; Tejera, E | 1 |
| Lu, F; Wang, B; Wang, Y; Xu, Y; Zhang, L; Zhang, M | 1 |
| Branco, J; Butler, G; Miranda, IM; Pinto E Silva, A; Rodrigues, AG; Ryan, AP | 1 |
| Goto, N; Hida, Y; Higashi, T; Iwasaki, H; Kodawara, T; Tsukamoto, H; Watanabe, K | 1 |
| de Lima-Neto, RG; de Melo, HRL; de Sousa, BR; Neves, RP; Silva, GM; Torres, KB | 1 |
| Argaud, L; Bestion, A; Bienvenu, AL; Guichon, C; Leboucher, G; Paillet, C; Piriou, V; Pradat, P; Richard, JC; Roux, S | 1 |
| Alt, V; Mannala, GK; Riool, M; Rupp, M; Scholz, KJ; Simon, M; Walter, N | 1 |
| Abdel-Hamid, RM; Abdelfattah, NE; El-Mahallawy, HA; Wassef, MA | 1 |
| Castanheira, M; Deshpande, LM; Messer, SA; Pfaller, MA; Rhomberg, PR | 1 |
| Corcione, S; D'Avolio, A; De Rosa, FG; Pagani, N; Pasero, D; Sanguinetti, M; Trentalange, A | 1 |
| Ahmad, S; Al-Sweih, N; Alfouzan, W; Joseph, L; Khan, Z | 1 |
| Gupta, MK; Pandey, N; Paul, P; Tilak, R | 1 |
| Brilhante, RSN; Caetano, ÉP; Castelo-Branco, DSCM; Cordeiro, RA; Guedes, GMM; Paiva, MAN; Rocha, MFG; Sidrim, JJC; Teixeira, CEC | 1 |
| Kakkassery, V; Kurzai, O; von Jagow, B | 1 |
| Bot, JCJ; de Leeuw, DC; Hendriks, EJ; Overgaauw, AJC; Stoof, SP; van Dijk, K | 1 |
| Capilla, J; Guarro, J; López-Fernández, L; Martin-Vicente, A; Navarro-Rodríguez, P | 2 |
| Berrocal, AM; El Hamichi, S; Gold, AS; Kon Graversen, V; Murray, TG | 1 |
| Bhagali, R; Prabhudesai, MN; Prabhudesai, NP | 1 |
| Bovone, C; Busin, M; Furiosi, L; Myerscough, J; Socea, S; Spena, R; Yu, AC | 1 |
| Abu Talib, DN; Bastion, MC; Che-Hamzah, J; Nasaruddin, RA; Yong, MH | 1 |
| Brandão, IB; Colombo, AL; de Almeida, SLR; de Andrade, TS; de Miranda Costa, MM; de Oliveira Dias, P; de Souza Jordão, RT; Francisco, EC; Meis, JF; Nobrega de Almeida, J; Pereira, FM; Santos Ferreira, F | 1 |
| Matsumoto, Y; Sugita, T; Yasu, T | 1 |
| Guo, Y; Huang, D; Li, X; Liu, L; Liu, Y; Nashan, B; Qin, J; Song, R; Wang, J; Wang, N; Wu, W; Xu, Z; Yao, Z; Zheng, H; Zhu, Z | 1 |
| Čurová, K; Hrabovská, Z; Hrabovský, V; Pastvová, L; Schréterová, E; Siegfried, L; Takáčová, V | 1 |
| Azeredo, J; Gonçalves, B; Henriques, M; Rodrigues, CF; Rodrigues, ME; Silva, S | 1 |
| Abbasi, SA; Bokhari, H; Hussain, Z; Imran, M; Jamil, B; Khalid, T; Mukhtar Bokhari, MT; Mukhtar Bokhari, MZ; Saeed, A | 1 |
| Chen, L; Dong, Y; Hao, R; Lei, J; Liu, L; Wang, X; Wang, Y; Xie, J; Yang, Q; Zhang, T | 1 |
| Faryal, R; Shah, AA; Siddiqui, MT; Tasneem, U | 1 |
| Aydin, F; Cebeci Güler, N; Tosun, I | 1 |
| Butler, G; Chibana, H; Güldener, U; Lopes, MM; Mira, NP; Münsterkötter, M; Okamoto, M; Salazar, SB; Takahashi-Nakaguchi, A; Wang, C | 1 |
| Chang, MR; Lima, GME; Mendes, RP; Negro, GMBD; Nunes, JO; Nunes, MO; Paniago, AMM; Taira, CL; Thomaz, DY; Tsujisaki, RAS | 1 |
| Ahangarkani, F; Aslani, N; Badali, H; Boekhout, T; Hagen, F; Kolecka, A; Meis, JF; Meyabadi, MF; Shokohi, T | 1 |
| Arwood, MJ; Bulitta, J; Cavallari, LH; Hamadeh, IS; Klinker, KP; Mangal, N; Samant, TS; Schmidt, S | 1 |
| Jamal, F; Karunanidhi, A; Madhavan, P; Ng, KP; Othman, F; Pei, CP | 1 |
| Bartoszewicz, M; Król, J; Nawrot, U | 1 |
| Aneji, C; Benjamin, DK; Domonoske, C; Mazur, L; Tsakiri, S; Wootton, SH | 1 |
| Chakrabarti, A; Kaur, K; Kumari, A; Sethi, P; Singh, R | 1 |
| Chaurasia, S; Joseph, J; Nagpal, R; Ramappa, M; Rani, PK; Shah, R; Tyagi, M | 1 |
| Abutaleb, NS; Eldesouky, HE; Li, X; Mohammad, H; Seleem, MN | 1 |
| Bilgihan, K; Erdoğan, M; Hizel, K; Kalkanci, A; Karakus, AK; Ozdemir, HB; Seker, T; Tum, AE; Unal, EA; Yesilirmak, N | 1 |
| Folić, M; Janković, SM; Jović, Z; Kostić, M; Milovanović, D; Milovanović, J; Ružić Zečević, D; Stefanović, S | 1 |
| Kader, NA; Patil, S; Raj, AT; Seetharam, C; Sujatha, G | 1 |
| Abbaszadeh, S; Sharifzadeh, A; Shokri, H | 1 |
| Imamura, Y; Izumikawa, K; Kohno, S; Minematsu, A; Miyazaki, T; Mukae, H; Nakayama, H; Nishikawa, H; Saijo, T; Shimamura, S; Takazono, T; Yamamoto, K; Yanagihara, K | 1 |
| Al Jalali, V; Eberl, S; Sauermann, R; Zeitlinger, M | 1 |
| Arastehfar, A; Boekhout, T; Brouwer, C; Charsizadeh, A; Daneshnia, F; Haas, PJ; Hagen, F; Khodavaisy, S; Najafzadeh, MJ; Pan, W; Roudbary, M; Salehi, MR; Zarrinfar, H; Zomorodian, K | 1 |
| Alós-Almiñana, M; Ezquer-Garín, C; Ferriols-Lisart, R; Guglieri-Lopez, B; Hernández-Boluda, JC; Navarro, D; Pérez, A; Perez-Pitarch, A; Piñana, JL; Solano, C | 1 |
| Bejou, N; Marr, K; McCarty, TP; Pappas, PG; Shields, RK; Wright, WF | 1 |
| Arora, R; Chaudhary, SC; Kumar, V; Sawlani, KK | 1 |
| Chu, HY; Fredricks, DN; Jain, R; Pottinger, P; Xie, H | 1 |
| Hamada, Y; Hirayama, T; Ichibe, Y; Katori, Y; Kuroyama, M; Okuma, R; Takahashi, S | 1 |
| Cuenca-Estrella, M; de Lucas, MP; Fusco-Almeida, AM; Lozano, E; Mendes-Giannini, MJ; Mesa-Arango, AC; Scorzoni, L; Zaragoza, O | 1 |
| Barrett, DM; Gerber, JS; Larru, B | 1 |
| Hatipoglu, H; Hatipoglu, N | 1 |
| Coste, A; Eddouzi, J; Ischer, F; Kelly, S; Manai, M; Parker, JE; Sanglard, D; Vale-Silva, LA | 1 |
| Chang, CL; Jang, HC; Jang, MJ; Kim, MN; Kim, SH; Lee, HS; Lee, K; Lee, MK; Lee, WG; Ryang, DW; Shin, JH; Shin, MG; Song, ES; Suh, SP | 1 |
| Arakawa, S; Fujisawa, M; Osawa, K; Shigemura, K; Yoshida, H | 1 |
| Ballot, DE; Bosman, N; Cooper, PA; Nana, T; Ramdin, T | 1 |
| Benjamin, DK; Ericson, J; Manzoni, P | 1 |
| Boral, OB; Cağatay, P; Keçeli, SA; Sonmez, N; Tamer, GS; Willke, A | 1 |
| Chen, SC; Meyer, W; Middleton, PG | 1 |
| Pea, F | 1 |
| Bierings, MB; Boelens, JJ; Gerhardt, CE; Hol, JA; Lindemans, CA; Versluys, AB; Wildt de, A; Wolfs, TF | 1 |
| Dorazilova, Z; Maly, J; Netuka, I; Pirk, J; Szarszoi, O | 1 |
| Gamaletsou, MN; Walsh, TJ | 1 |
| Cuenca-Estrella, M; Escribano, P; Guinea, J; Martín-Mazuelos, E; Pemán, J; Sánchez-Reus, F; Zaragoza, Ó | 1 |
| Biswas, P; Chin-Hong, P; Kett, DH; Pappas, PG; Patterson, TF; Reboli, AC; Reinhardt, J; Swanson, R; Tobin, E; Vazquez, J | 1 |
| Egrilmez, S; Gunduz, OU; Palamar, M; Polat, SH; Yilmaz, SG | 1 |
| Baliellas, C; Bodro, M; Carratalà, J; Fabregat, J; Lladó, L; Petit, A; Ramos, E; Sabé, N; Solé, C | 1 |
| Cevallos, V; Hoover, C; Jeng, BH; Keenan, JD; Layer, N; Maxwell, AJ | 1 |
| Faria-Ramos, I; Miranda, IM; Pina-Vaz, C; Ricardo, E; Rodrigues, AG; Silva, RM | 1 |
| Hou, J; Tu, EY | 1 |
| Adrados Calleja, R; Caceda Castañeda, BM; Cisterna Cancer, R; Unzaga Barañano, MJ | 1 |
| Tang, S | 1 |
| Colón, B; Flowers, SA; Rogers, PD; Schuler, MA; Whaley, SG | 1 |
| Kumar, A; Kumar, D; Singh, S; Tilak, R | 1 |
| Dugar, J; Miller, D; OʼBrien, TP; Spierer, O | 1 |
| El-Azizi, M; Farag, N; Khardori, N | 1 |
| Carver, PL; Pettit, NN | 1 |
| Nayyar, PM; Parikh, SA; Patel, VA; Ratner, D | 1 |
| Chlebicki, MP; Kwa, AL; Lee, W; Liew, YX; Ngan, CC; Tan, AL; Teo, J; Too, IA | 1 |
| Meletiadis, J; Siafakas, N; Siopi, M; Zerva, L | 1 |
| Carbajal, WH; Lozada, C; Reyes, HA; Valdez, LM | 1 |
| Capilla, J; Fothergill, AW; Guarro, J; Sanchis, M; Sutton, DA; Wiederhold, N | 1 |
| Coste, AT; Sanglard, D | 1 |
| Dokoumetzidis, A; Gamaletsou, M; Goussetis, E; Meletiadis, J; Neroutsos, E; Pirounaki, M; Siopi, M; Sipsas, N; Tsirigotis, P; Valsami, G; Zerva, L; Zisaki, K | 1 |
| Adjapong, G; Bartlett, M; Garrill, A; Hale, M | 1 |
| Hernández-Valles, R; Humbría-García, L; Saúl-García, Y | 1 |
| Ahmadi, MS; Davies, KP; Friedman, AJ; Lee, HH; Martinez, LR; Nosanchuk, JD; Sanchez, DA; Tar, MT | 1 |
| Capilla, J; Castanheira, M; Fothergill, AW; Guarro, J; Martin-Vicente, A; Sanchis, M; Sutton, DA; Wiederhold, NP | 1 |
| Ge, T; Li, N; Liao, S; Qi, F; Xu, G; Zhu, L | 1 |
| Arslan, U; Dagi, HT; Findik, D; Senkeles, C | 1 |
| Cadirci, E; Duzgun, E; Karagoz, E; Keles, S; Turhan, V; Ugan, RA; Uyanik, MH; Yavan, I | 1 |
| Das, PP; Nath, R; Phukan, SK; Saikia, L | 1 |
| Aram, JA; Capparella, MR; Conte, U; Liu, P; Macias-Parra, M; Martin, JM; Mudry, P; Yan, JL | 1 |
| Amirrajab, N; Badali, H; Gohar, AA; Moazeni, M; Nabili, M; Shokohi, T | 1 |
| Hsueh, PR; Wang, H; Xu, YC | 1 |
| Figiel, W; Krawczyk, M; Sulik-Tyszka, B; Wróblewska, M | 1 |
| Cen, W; Feng, W; Lv, Y; Ma, Y; Qiao, Z; Wang, Y; Xi, Z; Yang, J | 1 |
| Guo, H; Jiang, L; Li, DM; Li, SX; Song, YJ; Zhang, H; Zhao, YJ; Zhu, KJ | 1 |
| Brodmann, M; Gary, T; Hackl, G; Hafner, F; Jud, P; Regauer, S; Rief, P; Valentin, T | 1 |
| Ayala, J; Elizondo, M; González, GM | 1 |
| Dolande, M; Panizo, MM; Reviákina, V; Selgrad, S | 1 |
| Bosch, M; Cantón, E; Espinel-Ingroff, A; Gobernado, M; Pemán, J; Valentín, A | 1 |
| Hollenbach, E | 1 |
| Gafter-Gvili, A; Goldberg, E; Leibovici, L; Paul, M; Vidal, L | 1 |
| Espinel-Ingroff, A; Hockey, H; Johnson, E; Szekely, A; Troke, P | 1 |
| Aronoff, DM; Malani, AN | 1 |
| Choi, CW; Joo, SI; Kim, BS; Kim, EC; Kim, TU; Kim, YK; Lee, KM; Lee, YS; Yoo, JI; Yun, SH | 1 |
| Denning, DW; Majithiya, J; Parmar, A; Sharp, A; Warn, PA | 1 |
| da Silva, CF; Dalla Costa, T; de Araujo, BV; Haas, SE | 1 |
| Cubillos, GF; Kett, DH | 1 |
| Boyken, L; Diekema, DJ; Hollis, RJ; Jones, RN; Kroeger, J; Messer, SA; Pfaller, MA; Tendolkar, S | 1 |
| Nawrot, U; Nowicka, J; Wlodarczyk, K | 1 |
| Enache-Angoulvant, A; Girard, A; Hennequin, C; Poirot, JL | 1 |
| Marti, J | 1 |
| Asari, S; Iwatani, Y; Nishi, I; Sunada, A; Toyokawa, M | 1 |
| Fanci, R | 1 |
| Kim, SD; Lee, JJ; Lee, SJ | 1 |
| Clancy, CJ; Derendorf, H; Li, Y; Nguyen, MH; Schmidt, S; Zhong, L | 1 |
| Kida, M | 1 |
| Amrein, C; Benammar, M; Berge, M; Billaud, EM; Boussaud, V; Chevalier, P; Guillemain, R; Lefeuvre, S | 1 |
| Danzi, M; Marino, A; Mungiguerra, M; Pisano, L; Ricciardi, AM; Ricciardi, R | 1 |
| De Carolis, E; Fadda, G; Fiori, B; Florio, AR; La Sorda, M; Martucci, R; Posteraro, B; Sanglard, D; Sanguinetti, M | 1 |
| Pérez, P; Piñar, D; Quiles, JA; Reus, S | 1 |
| Bulut, Y; Günday, E; Güven, M; Yenişehirli, G | 1 |
| Berger, N; Bonatti, H; Geltner, C; Grif, K; Lass-Flörl, C; Lechner, M; Margreiter, R; Stelzmueller, I | 1 |
| Andrade, SE; Elizondo, M; González, GM; Portillo, OJ; Robledo, M; Rodríguez, C; Uscanga, GI | 1 |
| Avolio, M; Bruschetta, G; Camporese, A; De Rosa, R; Grosso, S | 1 |
| Fung, CP; Lee, N; Lee, SC; Lo, HJ; See, LC | 1 |
| Costa, CR; de Aquino Lemos, J; de Fátima Lisboa Fernandes, O; do Rosário Rodrigues Silva, M; Hasimoto e Souza, LK; Jesuíno, RS; Passos, XS | 1 |
| Damon, L; Guglielmo, BJ; Hwang, J; Kaplan, L; Linker, C; Martin, T; O'Malley, R; Sharma, M; Working, M | 1 |
| Azeredo, J; Henriques, M; Martins, M; Negri, M; Oliveira, R; Svidzinski, TI | 1 |
| Al-Badriyeh, D; Davies, GE; Kong, D; Leung, L; Stewart, K | 1 |
| Bertout, S; Bourgeois, N; Bousquet, PJ; Dehandschoewercker, L; Lachaud, L; Rispail, P | 1 |
| Adiri, Y; Karatela, S; Lyon, GM; Sunay, S | 1 |
| Furuya, A; Ida, K; Kato, M; Koh, K; Okamoto, T; Takita, J | 1 |
| Diekema, DJ; Ellis, D; Fu, W; Gibbs, DL; Ling, TA; Newell, VA; Pfaller, MA; Rodloff, A; Tullio, V | 1 |
| Besse, B; Hennequin, C; Le Pape, P; Loge, C; Morio, F | 1 |
| Barton, R; Bijie, H; Bille, J; Chang, SC; da Luz Martins, M; Diekema, DJ; Duse, A; Dzierzanowska, D; Ellis, D; Finquelievich, J; Gibbs, DL; Gould, I; Gur, D; Hoosen, A; Lee, K; Mallatova, N; Mallie, M; Newell, VA; Peng, NG; Petrikos, G; Pfaller, MA; Santiago, A; Trupl, J; VanDen Abeele, AM; Wadula, J; Zaidi, M | 1 |
| King, AL; Massey, HD; Stolk, MJ | 1 |
| Hou, Z; Li, C; Liu, G; Liu, Z; Lu, M; Sha, X; Tan, D; Xie, J; Xie, Y | 1 |
| Cisneros-Lanuza, A; Díaz-Llopis, M; Duch-Samper, A; Hurtado-Sarrió, M; Peman-Garcíia, J; Vazquez-Polo, A | 1 |
| Cordonnier, C; Cornely, OA; Flückiger, U; Frêre, P; Gachot, B; Heinz, WJ; Herbrecht, R; Lass-Flörl, C; Maertens, J; Marchetti, O; Ribaud, P; Thiebaut, A | 1 |
| Gyo, K; Hato, N; Hinohira, Y; Hyodo, J; Takahashi, H; Ugumori, T; Wakisaka, H | 1 |
| Boyken, L; Diekema, DJ; Hollis, RJ; Kroeger, J; Messer, SA; Pfaller, MA; Tendolkar, S | 1 |
| Ko, KS; Lee, JY; Peck, KR; Song, JH | 1 |
| Azevedo, AC; Bizerra, FC; Colombo, AL; da Matta, DA; de Almeida, LP; Rosas, R | 1 |
| Boyken, L; Diekema, DJ; Espinel-Ingroff, A; Hollis, RJ; Kroeger, J; Messer, SA; Pfaller, MA; Tendolkar, S | 1 |
| Bourgeois, N; Crouzet, J; Lachaud, L; Picard, E; Sotto, A | 1 |
| Flynn, HW; Liggett, PE; Scartozzi, R; Tom, D | 1 |
| Katragkou, A; Roilides, E | 1 |
| Alexander, BD; Andes, D; Arendrup, MC; Brown, SD; Chaturvedi, V; Diekema, DJ; Espinel-Ingroff, A; Fowler, CL; Ghannoum, MA; Johnson, EM; Knapp, CC; Motyl, MR; Ostrosky-Zeichner, L; Pfaller, MA; Walsh, TJ | 1 |
| George, J; Reboli, AC | 1 |
| Dag, I; Kiraz, N; Oz, Y | 1 |
| Bassetti, M; Molinari, MP; Mussap, M; Nicco, E; Taramasso, L; Viscoli, C | 1 |
| Bedin, M; D'Angelo, M; Gion, M; Grandesso, S; Mazzuccato, S; Sapino, B; Solinas, M | 1 |
| Lacroix, C; Le Pape, P; Miegeville, M; Morio, F; Pagniez, F | 1 |
| Cantón, E; Martínez, JP; Pemán, J; Valentín, A | 1 |
| Dag, I; Kiraz, N; Kiremitci, A; Metintas, S; Oz, Y | 1 |
| Maack, KH; Tarp, B | 1 |
| Bader, O; Gross, U; Hull, CM; Kelly, DE; Kelly, SL; Parker, JE; Warrilow, AG; Weig, M | 1 |
| Denes, E; Dupon, M; Fiorenza, F; Megherbi, M; Saint-Marcoux, F; Weinbreck, P | 1 |
| Chang, YF; Lee, FL; Lee, SM; Yang, CS | 1 |
| Choi, HJ; Ju, MY; Jung, SI; Kim, SH; Lee, K; Lee, WG; Park, YJ; Shin, JH | 1 |
| Borowiec-Chłopek, Z; Czepita, D; Giedrys-Kalemba, S; Karczewicz, D; Kot, J; Lachowicz, E | 1 |
| Datta, S; Goel, N; Oberoi, JK; Prasad, K; Raveendran, R; Wattal, C | 1 |
| Darouiche, RO; Kontoyiannis, DP; Lewis, RE; Prince, RA; Raad, II | 1 |
| Danielsen, R; Einarsdóttir, HM; Gottfredsson, M | 1 |
| Boyken, L; Diekema, DJ; Hollis, RJ; Messer, SA; Pfaller, MA | 1 |
| Bayer, A; Edwards, JE; Rieg, G; Spellberg, B | 1 |
| Ruhnke, M | 1 |
| de la Torre-Cisneros, J; DuPont, B; Espinel-Ingroff, A; Greenberg, RN; Johnson, E; Just-Nübling, G; Lutsar, I; Marr, KA; Perfect, JR; Schlamm, HT; Walsh, TJ | 1 |
| Boyken, L; Diekema, DJ; Hollis, RJ; Messer, SA; Pfaller, MA; Tendolkar, S | 2 |
| Ullmann, AJ | 1 |
| Fung, HB; Jeu, L; Lyakhovetskiy, AG; Piacenti, FJ | 1 |
| Almela, M; Danés, C; de la Bellacasa, JP; Espasa, M; Jiménez de Anta, MT; Jurado, A; Marco, F; Martínez, JA; Mensa, J | 1 |
| Benito, R; Gil, J; Ramírez de Ocáriz, I; Rezusta, A; Rubio Calvo, MC | 1 |
| Andes, D; Conklin, R; Marchillo, K; Stamstad, T | 1 |
| Dromer, F; Lamer, C; Le Guillou, JL; Le Jouan, M; Martinez, V; Tod, M | 1 |
| Kullberg, BJ; Ostrosky-Zeichner, L; Oude Lashof, AM; Rex, JH | 1 |
| Bliss, JM; Gigliotti, F; Wellington, M | 1 |
| Baron, EJ; Colombo, AL; de Bedout, C; del Palacio, A; Gibbs, DL; Girmenia, C; Hazen, KC; Sanchez-Sousa, A | 1 |
| Fujihara, N; Ichiyama, S; Iinuma, Y; Kudo, T; Saito, T; Takakura, S | 1 |
| Casal, M; Charriel, G; Linares, MJ; Solís, F | 1 |
| Dupont, B | 1 |
| Bastié, JN; Bretagne, S; Castaigne, S; Chehata, S; Cordonnier, C; Kuentz, M; Maury, S; Pautas, C; Ribaud, P | 1 |
| Innes, JR; Moss, PJ; Thaker, HR; Varma, D; Wedgwood, K | 1 |
| Rubin, ZA; Somani, J | 1 |
| Nolard, N; Swinne, D; Van der Flaes, M; Watelle, M | 1 |
| Bocanegera, R; Colombo, AL; Gonzalez, GM; Graybill, JR; Hernandez, S; McCarthy, DI; Najvar, LK | 1 |
| Drago, M; Morace, G; Scaltrito, MM | 1 |
| Bernhardt, H; Bernhardt, J; Knoke, M; Ludwig, K | 1 |
| Cheng, HH; Lo, HJ; Yang, YL | 1 |
| Balajee, SA; Englund, JA; Fredricks, DN; Imhof, A; Marr, KA | 1 |
| Kleinpeter, MA | 1 |
| Espinel-Ingroff, A; Jones, RN; Pfaller, MA | 1 |
| Jones, AL; Pai, MP | 1 |
| D'Antonio, D; Di Bonaventura, G; Picciani, C; Piccolomini, R; Spedicato, I | 1 |
| Carrilero, MJ; Granados, JM; Puerto, N | 1 |
| Friedman, GS; Mathis, AS; Shah, NK | 1 |
| Bansal, M; Fealy, S; Khazzam, M | 1 |
| Perfect, JR | 2 |
| Marr, K | 1 |
| Breit, SM; Grand, MG; Hariprasad, SM; Mieler, WF; Mills, MD; Shah, GK | 1 |
| Balwierz, W | 1 |
| Fabry, K; Nelen, G; Verheyden, F | 1 |
| Böhme, A; Haas, A; Maschmeyer, G | 1 |
| Jacobs, RF; Maples, HD; Muldrew, KM; Stowe, CD | 1 |
| Jang, GJ; Kim, KS; Lee, WK; Shin, WS | 1 |
| Kofla, G; Ruhnke, M | 1 |
| Aguado, JM; Cisneros, JM; Díaz Pedroche, C; Lumbreras, C | 1 |
| Barchiesi, F; Cuenca-Estrella, M; Espinel-Ingroff, A; Fothergill, A; Pfaller, MA; Rinaldi, M; Rodriguez-Tudela, JL; Verweij, PE | 1 |
| Bishara, J; Peled, N; Samra, Z; Yardeni, M | 1 |
| Argaud, L; Martin, O; Mohammedi, I; Piens, MA; Robert, D; Thiebaut, A | 1 |
| Nagino, K; Shirasawa, H | 1 |
| Chang, SC; Chen, YC; Hsieh, SM; Lee, HT; Pan, SC | 1 |
| Kumar, R; Naithani, R | 1 |
| Marik, PE; Raman, T | 1 |
| Kyo, T; Mikami, Y; Murayama, SY; Myoken, Y; Sugata, T | 1 |
| Carde, A; Faure, P; Papy, E; Ribaud, P; Touratier, S | 1 |
| Bal, AM | 1 |
| Andes, D; Chaturvedi, V; Diekema, DJ; Espinel-Ingroff, A; Ghannoum, MA; Johnson, EM; Odds, FC; Pfaller, MA; Rex, JH; Rinaldi, MG; Sheehan, DJ; Troke, P; Walsh, TJ; Warnock, DW | 1 |
| Castro-Orjales, MJ; Collell-Llach, MD; de la Torre-Fernández, MJ; Díaz-López, MD; León, C; López-Ciudad, V; Pérez de Juan-Romero, MA; Sanz-Rodríguez, C | 1 |
| Gribskov, JL; Kirby, KA; Marr, KA; Panackal, AA; Rinaldi, M; Staab, JF | 1 |
| Bosch, M; Cantón, E; de Llanos, R; Jarque, I; Molina, A; Pemán, J; Salavert, M | 1 |
| Black, TA; Hare, R; Loebenberg, D; Mann, PA; McNicholas, PM; Mendrick, CA; Norris, CC; Patel, R; Sabatelli, F | 1 |
| Akova, M; Sahin, GO | 1 |
| Aperis, G; Mylonakis, E | 1 |
| Baltch, AL; Bopp, LH; Michelsen, PB; Ritz, WJ; Smith, RP | 1 |
| Pemán, J; Zaragoza, R | 1 |
| Bäsecke, J; Glass, B; Perske, C; Rüchel, R | 1 |
| Barcs, I; Dóczi, I; Mestyán, G; Nagy, E; Nikolova, R; Puskás, E | 1 |
| Lill, H; Voigt, C | 1 |
| Aperis, G; Mylonakis, E; Spanakis, EK | 1 |
| Manfredi, R; Sabbatani, S | 1 |
| Chang, SC; Diekema, DJ; Erzsebet, P; Gibbs, DL; Kibbler, C; Mendez, M; Newell, VA; Pfaller, MA | 1 |
| Colombo, AL; Diekema, DJ; Gibbs, DL; Kibbler, C; Newell, VA; Ng, KP; Pfaller, MA | 1 |
| Carratalà, J; Garcia-Vidal, C | 1 |
| Alcoba-Flórez, J; Arévalo, MP; Arias, A; Moragues, MD; Pontón, J; Quindós, G; Salgado-Parreño, FJ | 1 |
| Corbett, JR; McKeown, PP; Tolland, JP | 1 |
| Benjamin, DK; Cotten, CM; Perfect, JR; Schell, WA; Smith, PB; Steinbach, WJ; Walsh, TJ | 1 |
| Araújo, CR; Costa, CR; e Souza, LK; Fernandes, Ode F; Nascimento, ES; Passos, XS; Sales, WS; Silva, Mdo R | 1 |
| Avci, B; Cetinkaya, Z; Ermis, SS; Inan, UU; Kusbeci, T; Ozturk, F; Yavas, G | 1 |
| Aoun, N; Baixench, MT; Bretagne, S; Dannaoui, E; Desnos-Ollivier, M; Garcia-Hermoso, D; Piketty, C; Ramires, S | 1 |
| Arendrup, MC; Denning, DW; Diekema, DJ; Pfaller, MA; Rex, JH | 1 |
| Evens, A; Frankfurt, O; Gordon, L; Mehta, J; Pi, J; Singhal, S; Tallman, M; Trifilio, S; Williams, S; Winter, J | 1 |
| Haas, A; Maschmeyer, G | 1 |
| Guarro, J; Pastor, FJ | 1 |
| Cesur, S; Kaynak, F; Ozçelik, B; Sipahi, B; Sultan, N | 1 |
| Gahn, B; Gramatzki, M; Repp, R; Schub, N | 1 |
| Chang, CL; Kim, MN; Kim, SH; Lee, HS; Lee, JS; Lee, K; Lee, WG; Ryang, DW; Shin, BM; Shin, JH; Shin, MG; Suh, SP; Uh, Y | 1 |
| Khakoo, RA; Khan, FA; Slain, D | 1 |
| Alkorta, M; Eraso, E; Hernández-Almaraz, JL; Quindós, G; Sánchez-Vargas, LO; Villar-Vidal, M | 1 |
| Mian, P; Pagani, L; Spoladore, G; Vedovelli, C | 1 |
| Bille, J; Bolay, S; Buclin, T; Calandra, T; Marchetti, O; Pascual, A | 1 |
| Alffenaar, JW; Doedens, RA; Groninger, E; Kosterink, JG | 1 |
| Barnes, R; Colombo, A; Diekema, DJ; Finquelievich, J; Gibbs, DL; Newell, VA; Ng, KP; Pfaller, MA; Wadula, J | 1 |
| Imhof, A; Misselwitz, B; Schneemann, M | 1 |
| Joshi, R; Kohli, V; Sachdev, P; Taneja, V | 1 |
| Mercier, RC; Pai, MP; Samples, ML; Spilde, MN | 1 |
| Akşit, F; Kiraz, N; Kiremitçi, A; Oz, Y | 1 |
| Jones, RN; Marco, F; Messer, S; Pfaller, MA | 1 |
| Brandt, ME; Doern, GV; Hajjeh, RA; Hollis, RJ; Jones, RN; Messer, SA; Pfaller, MA | 1 |
| Coleman, DC; Gee, S; Joly, S; Messer, SA; Pfaller, MA; Pujol, C; Soll, DR; Sullivan, DJ | 1 |
| Bhat, N; Ghannoum, MA; Okogbule-Wonodi, I; Sanati, H | 1 |
| Patterson, TF | 1 |
| Niki, Y | 1 |
| Cassone, A; Girmenia, C; Martino, P; Monaco, M; Mondello, F; Santilli, S; Tuccinardi, C | 1 |
| Abdel-Rahman, SM; Sabo, JA | 1 |
| Bolmstrom, A; Houston, A; Jones, RN; Messer, SA; Mills, K; Pfaller, MA | 1 |
| Arikan, S; Kocagöz, S; Sancak, B; Unal, S; Uzun, O | 1 |
| Müller, FM; Weig, M | 1 |
| Karlsson, I; Kronvall, G | 1 |
| Czaika, V; Schmalreck, A; Schultze, W; Sterry, W; Tietz, HJ | 1 |
| Diekema, DJ; Fluit, AC; Hollis, RJ; Jones, RN; Messer, SA; Pfaller, MA; Sader, HS | 1 |
| Aguirrebengoa, K; Ally, R; Carosi, G; Dupont, B; Hodges, M; Kreisel, W; Romero, AJ; Schürmann, D; Troke, P | 1 |
| DE Carolis, E; Loranger, L; Marcotte, H; Pelletier, R | 1 |
| Diekema, DJ; Hollis, RJ; Jones, RN; Messer, SA; Pfaller, MA | 1 |
| Ghannoum, MA; Kuhn, DM | 1 |
| Habel, F; Hoban, D; Laverdiere, M; Restieri, C | 1 |
42 review(s) available for voriconazole and Candidiasis
| Article | Year |
|---|---|
Prevalence of biofilms in Candida spp. bloodstream infections: A meta-analysis.
Topics: Biofilms; Candida; Candidemia; Candidiasis; Caspofungin; Drug Resistance, Fungal; Fluconazole; Hospitalization; Humans; Prevalence; Sepsis; Voriconazole | 2022 |
Clinical Pharmacokinetics of Second-Generation Triazoles for the Treatment of Invasive Aspergillosis and Candidiasis.
Topics: Animals; Antifungal Agents; Aspergillosis; Candidiasis; Drug Interactions; Humans; Triazoles; Voriconazole | 2019 |
Molecular characterization and antifungal susceptibility testing of Candida nivariensis from blood samples - an Iranian multicentre study and a review of the literature.
Topics: Adolescent; Aged; Amphotericin B; Amplified Fragment Length Polymorphism Analysis; Antifungal Agents; Bronchoalveolar Lavage; Candida; Candidemia; Candidiasis; Caspofungin; DNA, Intergenic; Fatal Outcome; Female; Fluconazole; Genotype; Humans; Iran; Male; Microbial Sensitivity Tests; Middle Aged; Polymerase Chain Reaction; Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization; Vagina; Voriconazole | 2019 |
Bibliographical investigation (domestic and overseas) on the treatment of endogenous Candida endophthalmitis over an 11-year period.
Topics: Adolescent; Adult; Aged; Amphotericin B; Antifungal Agents; Candida albicans; Candidiasis; Endophthalmitis; Female; Fluconazole; Humans; Infant; Japan; Male; MEDLINE; Middle Aged; Pyrimidines; Severity of Illness Index; Time Factors; Treatment Outcome; Triazoles; Vitrectomy; Voriconazole; Young Adult | 2013 |
Combination antifungal therapy for invasive fungal infections in children and adults.
Topics: Adult; Amphotericin B; Antifungal Agents; Aspergillosis; Aspergillus; Candida; Candidiasis; Caspofungin; Child; Cryptococcosis; Cryptococcus; Drug Therapy, Combination; Echinocandins; Humans; Lipopeptides; Pyrimidines; Triazoles; Voriconazole | 2013 |
Background changing patterns of neonatal fungal sepsis in a developing country.
Topics: Antifungal Agents; Birth Weight; Candida; Candidemia; Candidiasis; Drug Resistance, Fungal; Female; Fluconazole; Humans; Incidence; Infant, Newborn; Male; Microbial Sensitivity Tests; Pyrimidines; Risk Factors; Socioeconomic Factors; South Africa; Treatment Outcome; Triazoles; Voriconazole | 2013 |
Old and new: appropriate dosing for neonatal antifungal drugs in the nursery.
Topics: Amphotericin B; Antifungal Agents; Candidiasis; Deoxycholic Acid; Dose-Response Relationship, Drug; Drug Combinations; Echinocandins; Fluconazole; Humans; Infant, Newborn; Infant, Newborn, Diseases; Intensive Care Units, Neonatal; Neonatology; Pyrimidines; Triazoles; Voriconazole | 2013 |
Fungal infections and treatment in cystic fibrosis.
Topics: Antibodies, Fungal; Antifungal Agents; Aspergillosis; Aspergillus; Aspergillus fumigatus; Bronchoalveolar Lavage Fluid; Candida; Candidiasis; Cystic Fibrosis; DNA, Fungal; Female; Humans; Itraconazole; Male; Pyrimidines; Scedosporium; Sputum; Triazoles; Vital Capacity; Voriconazole | 2013 |
Current pharmacological concepts for wise use of echinocandins in the treatment of Candida infections in septic critically ill patients.
Topics: Amphotericin B; Antifungal Agents; Candida; Candidiasis; Critical Illness; Drug Administration Schedule; Drug Dosage Calculations; Drug Therapy, Combination; Echinocandins; Humans; Practice Guidelines as Topic; Pyrimidines; Sepsis; Triazoles; Voriconazole | 2013 |
Fungal infections associated with long-term mechanical circulatory support-diagnosis and management.
Topics: Antifungal Agents; Aspergillosis; Candidiasis; Fluconazole; Heart Failure; Heart-Assist Devices; Humans; Incidence; Mycoses; Pyrimidines; Risk Factors; Time Factors; Triazoles; Voriconazole | 2014 |
Treatment of fungal disease in the setting of neutropenia.
Topics: Anemia, Aplastic; Antifungal Agents; Candida glabrata; Candidiasis; Drug Resistance, Fungal; Fusariosis; Fusarium; Hematologic Neoplasms; Humans; Myelodysplastic Syndromes; Neutropenia; Pyrimidines; Scedosporium; Triazoles; Voriconazole | 2013 |
Isavuconazole: A New Option for the Management of Invasive Fungal Infections.
Topics: Animals; Antifungal Agents; Aspergillosis; Candidemia; Candidiasis; Candidiasis, Invasive; Clinical Trials as Topic; Drug Resistance, Fungal; Humans; Nitriles; Pyridines; Triazoles; Voriconazole | 2015 |
Epidemiology of candidemia and antifungal susceptibility in invasive Candida species in the Asia-Pacific region.
Topics: Anidulafungin; Antifungal Agents; Asia; Azoles; Candida; Candida albicans; Candida glabrata; Candida tropicalis; Candidemia; Candidiasis; Candidiasis, Invasive; Drug Resistance, Fungal; Echinocandins; Fluconazole; Humans; Incidence; Itraconazole; Lipopeptides; Micafungin; Microbial Sensitivity Tests; Phenotype; Prevalence; Voriconazole | 2016 |
Invasive candidiasis in the ICU: evidence based and on the edge of evidence.
Topics: Amphotericin B; Antifungal Agents; Candida; Candidiasis; Cross Infection; Deoxycholic Acid; Drug Combinations; Drug Therapy, Combination; Echinocandins; Fluconazole; Humans; Intensive Care Units; Itraconazole; Pyrimidines; Risk Factors; Triazoles; Voriconazole | 2008 |
Treatment of invasive candidal infections: systematic review and meta-analysis.
Topics: Amphotericin B; Antifungal Agents; Candidiasis; Caspofungin; Confidence Intervals; Drug Therapy, Combination; Echinocandins; Fluconazole; Humans; Itraconazole; Lipopeptides; Lipoproteins; Micafungin; Odds Ratio; Pyrimidines; Treatment Outcome; Triazoles; Voriconazole | 2008 |
Anidulafungin in the treatment of patients with invasive candidiasis.
Topics: Anidulafungin; Antifungal Agents; Candida; Candidiasis; Echinocandins; Fluconazole; Humans; Pyrimidines; Triazoles; Voriconazole | 2008 |
Screening for amino acid substitutions in the Candida albicans Erg11 protein of azole-susceptible and azole-resistant clinical isolates: new substitutions and a review of the literature.
Topics: Amino Acid Substitution; Antifungal Agents; Candida albicans; Candidiasis; Cytochrome P-450 Enzyme System; DNA, Fungal; Drug Resistance, Fungal; Fluconazole; Fungal Proteins; Humans; Itraconazole; Microbial Sensitivity Tests; Molecular Sequence Data; Mutation, Missense; Pyrimidines; Sequence Analysis, DNA; Sterol 14-Demethylase; Triazoles; Voriconazole | 2010 |
Best practice in treating infants and children with proven, probable or suspected invasive fungal infections.
Topics: Antifungal Agents; Aspergillosis; Candidiasis; Child; Echinocandins; Fever of Unknown Origin; Humans; Infant; Mycoses; Pyrimidines; Triazoles; Voriconazole | 2011 |
Clinical breakpoints for voriconazole and Candida spp. revisited: review of microbiologic, molecular, pharmacodynamic, and clinical data as they pertain to the development of species-specific interpretive criteria.
Topics: Antifungal Agents; Candida; Candidiasis; Humans; Microbial Sensitivity Tests; Pyrimidines; Triazoles; Voriconazole | 2011 |
Anidulafungin: when and how? The clinician's view.
Topics: Anidulafungin; Antifungal Agents; Aspergillosis; Aspergillus; Candida; Candidiasis; Drug Resistance, Fungal; Drug Synergism; Drug-Related Side Effects and Adverse Reactions; Echinocandins; Humans; Itraconazole; Microbial Sensitivity Tests; Pyrimidines; Triazoles; Voriconazole | 2012 |
[Voriconazole - applications and perspectives].
Topics: Antifungal Agents; Aspergillosis; Candidiasis; Humans; Microbial Sensitivity Tests; Mitosporic Fungi; Pyrimidines; Triazoles; Voriconazole | 2002 |
Review of the safety, tolerability, and drug interactions of the new antifungal agents caspofungin and voriconazole.
Topics: Antifungal Agents; Aspergillosis; Candidiasis; Caspofungin; Clinical Trials as Topic; Drug Interactions; Echinocandins; Humans; Lipopeptides; Peptides; Peptides, Cyclic; Pyrimidines; Treatment Outcome; Triazoles; Voriconazole | 2003 |
Voriconazole.
Topics: Animals; Antifungal Agents; Area Under Curve; Aspergillosis; Candidiasis; Child; Child, Preschool; Female; Fungi; Half-Life; Humans; Intestinal Absorption; Male; Microbial Sensitivity Tests; Pyrimidines; Randomized Controlled Trials as Topic; Scedosporium; Tissue Distribution; Triazoles; Voriconazole; Yeasts | 2003 |
Antifungal pharmacotherapy for neonatal candidiasis.
Topics: Amphotericin B; Antifungal Agents; Candidiasis; Caspofungin; Cross Infection; Echinocandins; Fluconazole; Flucytosine; Fungal Proteins; Fungemia; Humans; Infant, Newborn; Infant, Premature; Intensive Care Units, Neonatal; Ketoconazole; Lipopeptides; Peptides; Peptides, Cyclic; Pyrimidines; Triazoles; Voriconazole | 2003 |
[New antifungal agents: voriconazole and caspofungin].
Topics: Antifungal Agents; Aspergillosis; Candidiasis; Caspofungin; Child; Drug Interactions; Echinocandins; Humans; Lipopeptides; Peptides; Peptides, Cyclic; Pyrimidines; Triazoles; Voriconazole | 2003 |
New options for the treatment of invasive fungal infections.
Topics: Adult; Antifungal Agents; Aspergillosis; Candidiasis; Caspofungin; Echinocandins; Female; Fungemia; Humans; Immunocompromised Host; Lipopeptides; Male; Middle Aged; Mycetoma; Mycoses; Neoplasms; Opportunistic Infections; Peptides; Peptides, Cyclic; Pyrimidines; Scedosporium; Triazoles; Voriconazole | 2004 |
Successful treatment of Candida infections in peritoneal dialysis patients: case reports and review of the literature.
Topics: Aged; Antifungal Agents; Candidiasis; Catheters, Indwelling; Cefazolin; Female; Humans; Middle Aged; Peritoneal Dialysis; Peritonitis; Pyrimidines; Triazoles; Voriconazole | 2004 |
Use of newer antifungal therapies in clinical practice: what do the data tell us?
Topics: Amphotericin B; Antifungal Agents; Aspergillosis; Candidiasis; Caspofungin; Deoxycholic Acid; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Combinations; Drug Resistance, Fungal; Echinocandins; Humans; Lipopeptides; Liposomes; Mycoses; Peptides, Cyclic; Phosphatidylcholines; Phosphatidylglycerols; Pyrimidines; Randomized Controlled Trials as Topic; Time Factors; Treatment Outcome; Triazoles; Voriconazole; Zygomycosis | 2004 |
Combination antifungal therapy: where are we now, and where are we going?
Topics: Amphotericin B; Animals; Antifungal Agents; Aspergillosis; Azoles; Candidiasis; Caspofungin; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Echinocandins; Fluconazole; Humans; In Vitro Techniques; Lipopeptides; Lipoproteins; Micafungin; Mycoses; Peptides, Cyclic; Pyrimidines; Randomized Controlled Trials as Topic; Time Factors; Treatment Outcome; Triazoles; Voriconazole | 2004 |
Antifungal resistance: the clinical front.
Topics: Amphotericin B; Antifungal Agents; Candida; Candidiasis; Caspofungin; Drug Resistance, Fungal; Echinocandins; Fluconazole; Health Status; Humans; Lipopeptides; Peptides, Cyclic; Pyrimidines; Risk Factors; Thiazoles; Treatment Outcome; Triazoles; United States; Voriconazole | 2004 |
[Update on therapy of invasive mycoses in hematology and oncology].
Topics: Amphotericin B; Antifungal Agents; Aspergillosis; Candidiasis; Caspofungin; Deoxycholic Acid; Drug Combinations; Echinocandins; Hematologic Neoplasms; Humans; Itraconazole; Lipopeptides; Liposomes; Mycoses; Organ Transplantation; Peptides, Cyclic; Pyrimidines; Risk Factors; Stem Cell Transplantation; Triazoles; Voriconazole; Zygomycosis | 2005 |
Voriconazole: review of a broad spectrum triazole antifungal agent.
Topics: Administration, Oral; Animals; Antifungal Agents; Aspergillosis; Candidiasis; Caspofungin; Cryptococcosis; Cyclic N-Oxides; Disease Models, Animal; Drug Resistance, Fungal; Drug Therapy, Combination; Echinocandins; Fluconazole; Humans; Injections, Intravenous; Lipopeptides; Microbial Sensitivity Tests; Mycoses; Peptides, Cyclic; Pyrimidines; Randomized Controlled Trials as Topic; Triazoles; Voriconazole | 2005 |
[Voriconazole-medicalneeds, evidence, potential for the future].
Topics: Animals; Antifungal Agents; Aspergillosis; Aspergillus; Biological Availability; Candida; Candidiasis; Guinea Pigs; Humans; Pyrimidines; Tissue Distribution; Triazoles; Voriconazole | 2005 |
Fungal infections in bone marrow transplant recipients.
Topics: Amphotericin B; Antifungal Agents; Aspergillosis; Bone Marrow Transplantation; Candidiasis; Caspofungin; Drug Administration Schedule; Echinocandins; Humans; Lipopeptides; Peptides, Cyclic; Postoperative Complications; Premedication; Pyrimidines; Randomized Controlled Trials as Topic; Triazoles; Voriconazole | 2006 |
Treatment of invasive infections due to rare or emerging yeasts and moulds.
Topics: Amphotericin B; Animals; Antifungal Agents; Aspergillosis; Candidiasis; Clinical Trials as Topic; Drug Administration Schedule; Drug Resistance, Fungal; Drug Therapy, Combination; Fluconazole; Humans; Immunocompromised Host; Mucormycosis; Practice Guidelines as Topic; Pyrimidines; Triazoles; Voriconazole | 2006 |
Newer triazole antifungal agents: pharmacology, spectrum, clinical efficacy and limitations.
Topics: Animals; Antifungal Agents; Aspergillosis; Candidiasis; Cryptococcosis; Drug Administration Schedule; Drug Evaluation, Preclinical; Drug Resistance, Fungal; Drug Therapy, Combination; Humans; Pyrimidines; Randomized Controlled Trials as Topic; Thiazoles; Triazoles; Voriconazole | 2006 |
Invasive fungal infections in critically ill patients: different therapeutic options and a uniform strategy.
Topics: Amphotericin B; Antifungal Agents; Candidiasis; Critical Illness; Cross Infection; Deoxycholic Acid; Drug Combinations; Fluconazole; Humans; Intensive Care Units; Mycoses; Pyrimidines; Randomized Controlled Trials as Topic; Triazoles; Voriconazole | 2006 |
New agents for the treatment of fungal infections: clinical efficacy and gaps in coverage.
Topics: Antifungal Agents; Aspergillosis; Candidiasis; Caspofungin; Clinical Trials as Topic; Cryptococcosis; Echinocandins; Fever; Humans; Lipopeptides; Lipoproteins; Micafungin; Mycoses; Neutropenia; Peptides, Cyclic; Pyrimidines; Treatment Outcome; Triazoles; Voriconazole | 2006 |
[The role of voriconazole in the treatment of emerging mycoses].
Topics: Antifungal Agents; Aspergillosis; Candidiasis; Communicable Diseases, Emerging; Fusarium; Humans; Mycoses; Opportunistic Infections; Paecilomyces; Pyrimidines; Scedosporium; Triazoles; Voriconazole | 2007 |
Candida endophthalmitis: focus on current and future antifungal treatment options.
Topics: Amphotericin B; Antifungal Agents; Candidiasis; Echinocandins; Endophthalmitis; Fluconazole; Flucytosine; Humans; Pyrimidines; Risk Factors; Triazoles; Voriconazole | 2007 |
Role of newer azoles in surgical patients.
Topics: Antifungal Agents; Azoles; Candidiasis; Cross Infection; Dose-Response Relationship, Drug; Drug Design; Fluconazole; Humans; Pyrimidines; Surgical Wound Infection; Triazoles; Voriconazole | 1999 |
Voriconazole -- better chances for patients with invasive mycoses.
Topics: Antifungal Agents; Candida; Candidiasis; Drug Interactions; Drug Resistance, Fungal; Drug Tolerance; Humans; Mycoses; Pyrimidines; Safety; Triazoles; Voriconazole | 2002 |
6 trial(s) available for voriconazole and Candidiasis
| Article | Year |
|---|---|
Variability of voriconazole plasma levels measured by new high-performance liquid chromatography and bioassay methods.
Topics: Adult; Antifungal Agents; Area Under Curve; Biological Assay; Candida albicans; Candidiasis; Chromatography, High Pressure Liquid; Female; Humans; Male; Metabolic Clearance Rate; Microbial Sensitivity Tests; Middle Aged; Mutation; Pyrimidines; Reproducibility of Results; Spectrophotometry, Ultraviolet; Treatment Outcome; Triazoles; Voriconazole | 2007 |
Evaluation of an early step-down strategy from intravenous anidulafungin to oral azole therapy for the treatment of candidemia and other forms of invasive candidiasis: results from an open-label trial.
Topics: Administration, Intravenous; Administration, Oral; Adult; Aged; Aged, 80 and over; Anidulafungin; Antifungal Agents; Candida; Candidemia; Candidiasis; Candidiasis, Invasive; Echinocandins; Female; Fluconazole; Humans; Male; Middle Aged; Republic of Korea; Research Design; Risk; Treatment Outcome; United States; Voriconazole; Young Adult | 2014 |
Safety, Efficacy, and Exposure-Response of Voriconazole in Pediatric Patients With Invasive Aspergillosis, Invasive Candidiasis or Esophageal Candidiasis.
Topics: Adolescent; Antifungal Agents; Aspergillosis; Candidiasis; Candidiasis, Invasive; Child; Child, Preschool; Female; Humans; Male; Prospective Studies; Voriconazole | 2017 |
Voriconazole treatment for less-common, emerging, or refractory fungal infections.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antifungal Agents; Aspergillosis; Candidiasis; Child; Humans; Middle Aged; Pyrimidines; Treatment Outcome; Triazoles; Voriconazole | 2003 |
Correlation of MIC with outcome for Candida species tested against voriconazole: analysis and proposal for interpretive breakpoints.
Topics: Antifungal Agents; Candida; Candidiasis; Data Interpretation, Statistical; Drug Resistance, Fungal; Endpoint Determination; Fluconazole; Humans; Inhibitory Concentration 50; Microbial Sensitivity Tests; Pyrimidines; Triazoles; Voriconazole | 2006 |
A randomized, double-blind, double-dummy, multicenter trial of voriconazole and fluconazole in the treatment of esophageal candidiasis in immunocompromised patients.
Topics: Adolescent; Adult; Aged; Antifungal Agents; Candidiasis; Consumer Product Safety; Double-Blind Method; Esophageal Diseases; Female; Fluconazole; Humans; Immunocompromised Host; Male; Microbial Sensitivity Tests; Middle Aged; Pyrimidines; Treatment Outcome; Triazoles; Voriconazole | 2001 |
263 other study(ies) available for voriconazole and Candidiasis
| Article | Year |
|---|---|
New azole antifungals. 2. Synthesis and antifungal activity of heterocyclecarboxamide derivatives of 3-amino-2-aryl-1-azolyl-2-butanol.
Topics: Animals; Antifungal Agents; Aspergillosis; Aspergillus fumigatus; Candidiasis; Colony Count, Microbial; Fungi; Male; Mice; Molecular Conformation; Pyrimidinones; Rats; Stereoisomerism; Structure-Activity Relationship; Thiazoles; Thiophenes; Triazoles | 1998 |
New azole antifungals. 3. Synthesis and antifungal activity of 3-substituted-4(3H)-quinazolinones.
Topics: Animals; Antifungal Agents; Aspergillosis; Aspergillus fumigatus; Candidiasis; Colony Count, Microbial; Fungi; Male; Mice; Molecular Conformation; Quinazolines; Rabbits; Rats; Rats, Sprague-Dawley; Stereoisomerism; Structure-Activity Relationship; Triazoles | 1998 |
Reduced susceptibility to polyenes associated with a missense mutation in the ERG6 gene in a clinical isolate of Candida glabrata with pseudohyphal growth.
Topics: Antifungal Agents; Candida glabrata; Candidiasis; DNA Primers; Genes, Fungal; Genetic Complementation Test; Methyltransferases; Microbial Sensitivity Tests; Molecular Sequence Data; Mutation, Missense; Phenotype; Polyenes; Reverse Transcriptase Polymerase Chain Reaction; RNA, Fungal; RNA, Messenger; Sterols | 2007 |
Measurement of voriconazole activity against Candida albicans, C. glabrata, and C. parapsilosis isolates using time-kill methods validated by high-performance liquid chromatography.
Topics: Antifungal Agents; Candida; Candida albicans; Candida glabrata; Candidiasis; Chromatography, High Pressure Liquid; Culture Media; Dose-Response Relationship, Drug; Fungemia; Humans; Microbial Sensitivity Tests; Pyrimidines; Time Factors; Triazoles; Voriconazole | 2007 |
Antimicrobial activity of omiganan pentahydrochloride against contemporary fungal pathogens responsible for catheter-associated infections.
Topics: Antifungal Agents; Antimicrobial Cationic Peptides; Aspergillosis; Aspergillus; Candida; Candidiasis; Catheterization, Central Venous; Dose-Response Relationship, Drug; Drug Resistance, Fungal; Fungemia; Fungi; Humans; Microbial Sensitivity Tests | 2008 |
In vitro and in vivo antifungal activities of T-2307, a novel arylamidine.
Topics: Animals; Antifungal Agents; Aspergillosis; Aspergillus fumigatus; Benzamidines; Candida albicans; Candidiasis; Cryptococcosis; Cryptococcus neoformans; Male; Mice; Mice, Inbred ICR; Microbial Sensitivity Tests; Mycoses; Specific Pathogen-Free Organisms; Treatment Outcome | 2008 |
Prevalence and susceptibility profile of Candida metapsilosis and Candida orthopsilosis: results from population-based surveillance of candidemia in Spain.
Topics: Antifungal Agents; Candida; Candidiasis; Fungemia; Humans; Microbial Sensitivity Tests; Population Surveillance; Prevalence; Spain; Species Specificity | 2008 |
Reduced Candida glabrata susceptibility secondary to an FKS1 mutation developed during candidemia treatment.
Topics: Aged; Antifungal Agents; Candida glabrata; Candidiasis; Caspofungin; Drug Resistance, Fungal; Echinocandins; Fatal Outcome; Female; Fungal Proteins; Fungemia; Glucosyltransferases; Humans; Lipopeptides; Membrane Proteins; Microbial Sensitivity Tests; Mutation | 2008 |
In vitro activity of anidulafungin against Candida albicans biofilms.
Topics: Anidulafungin; Antifungal Agents; Biofilms; Candida albicans; Candidiasis; Drug Resistance, Fungal; Echinocandins; Humans; Microbial Sensitivity Tests | 2008 |
A nonsense mutation in the ERG6 gene leads to reduced susceptibility to polyenes in a clinical isolate of Candida glabrata.
Topics: Antifungal Agents; Azoles; Base Sequence; Candida glabrata; Candidiasis; Codon, Nonsense; DNA, Fungal; Drug Resistance, Fungal; Ergosterol; Genes, Fungal; Guanine; Humans; Molecular Sequence Data; Polyenes | 2008 |
Caspofungin-resistant Candida tropicalis strains causing breakthrough fungemia in patients at high risk for hematologic malignancies.
Topics: Aged; Aged, 80 and over; Antifungal Agents; Candida tropicalis; Candidiasis; Caspofungin; Drug Resistance, Fungal; Echinocandins; Fungemia; Hematologic Neoplasms; Humans; Lipopeptides; Male; Middle Aged | 2008 |
Abc1p is a multidrug efflux transporter that tips the balance in favor of innate azole resistance in Candida krusei.
Topics: Amino Acid Sequence; Animals; Antifungal Agents; ATP-Binding Cassette Transporters; Azoles; Blotting, Northern; Blotting, Southern; Candida; Candidiasis; Cell Membrane; Chromosomes, Fungal; Drug Resistance, Fungal; Endoplasmic Reticulum; Humans; Phenotype; Plasmids; Reverse Transcriptase Polymerase Chain Reaction; Saccharomyces cerevisiae | 2009 |
Breakthrough Aspergillus fumigatus and Candida albicans double infection during caspofungin treatment: laboratory characteristics and implication for susceptibility testing.
Topics: Animals; Antifungal Agents; Aspergillosis; Aspergillus fumigatus; Candida albicans; Candidiasis; Caspofungin; Colony Count, Microbial; Echinocandins; Humans; Immunohistochemistry; Injections, Intraperitoneal; Lipopeptides; Mice; Mice, Inbred Strains; Microbial Sensitivity Tests; Polymerase Chain Reaction | 2009 |
A 10-year survey of antifungal susceptibility of candidemia isolates from intensive care unit patients in Greece.
Topics: Antifungal Agents; Candida; Candidiasis; Data Collection; Disease Susceptibility; Greece; Humans; Intensive Care Units; Microbial Sensitivity Tests; Retrospective Studies | 2009 |
Efficacy of triazoles in a murine disseminated infection by Candida krusei.
Topics: Amphotericin B; Animals; Antifungal Agents; Candida; Candidiasis; Kidney; Male; Mice; Pyrimidines; Random Allocation; Triazoles; Voriconazole | 2009 |
Anidulafungin treatment of candidal central nervous system infection in a murine model.
Topics: Amphotericin B; Anidulafungin; Animals; Antifungal Agents; Candida albicans; Candidiasis; Central Nervous System Infections; Disease Models, Animal; Echinocandins; Female; Mice; Pyrimidines; Triazoles; Voriconazole | 2009 |
Acquisition of flucytosine, azole, and caspofungin resistance in Candida glabrata bloodstream isolates serially obtained from a hematopoietic stem cell transplant recipient.
Topics: Antifungal Agents; Azoles; Candida glabrata; Candidiasis; Caspofungin; Child; Drug Resistance, Fungal; Echinocandins; Female; Flucytosine; Fungal Proteins; Fungemia; Hematopoietic Stem Cell Transplantation; Humans; Lipopeptides; Microbial Sensitivity Tests; Point Mutation | 2010 |
Genetic dissection of azole resistance mechanisms in Candida albicans and their validation in a mouse model of disseminated infection.
Topics: Animals; Antifungal Agents; Base Sequence; Candida albicans; Candidiasis; Disease Models, Animal; DNA Primers; DNA, Fungal; Drug Resistance, Fungal; Female; Fluconazole; Fungal Proteins; Genes, Fungal; Genetic Engineering; Humans; In Vitro Techniques; Membrane Transport Proteins; Mice; Mice, Inbred BALB C; Microbial Sensitivity Tests; Mutation | 2010 |
Roles of calcineurin and Crz1 in antifungal susceptibility and virulence of Candida glabrata.
Topics: Animals; Antifungal Agents; Base Sequence; Calcineurin; Candida glabrata; Candidiasis; DNA Primers; DNA, Fungal; Drug Resistance, Fungal; Female; Fungal Proteins; Genes, Fungal; Humans; In Vitro Techniques; Mice; Mice, Inbred BALB C; Microbial Sensitivity Tests; Mutation; Opportunistic Infections; Transcription Factors; Virulence | 2010 |
Novel alkylated azoles as potent antifungals.
Topics: Alkylation; Animals; Antifungal Agents; Azoles; Candida albicans; Candidiasis; Cell Line; Ergosterol; Fungi; Hemolysis; Humans; Mice; Microbial Sensitivity Tests; Mycoses | 2017 |
New azole antifungals with a fused triazinone scaffold.
Topics: Animals; Antifungal Agents; Candida albicans; Candidiasis; Drug Resistance, Fungal; Mice; Microbial Sensitivity Tests; Molecular Structure; Structure-Activity Relationship; Triazines | 2020 |
Discovery of Novel Fungal Lanosterol 14α-Demethylase (CYP51)/Histone Deacetylase Dual Inhibitors to Treat Azole-Resistant Candidiasis.
Topics: 14-alpha Demethylase Inhibitors; Animals; Azoles; Candida albicans; Candidiasis; Cytochrome P450 Family 51; Drug Discovery; Drug Resistance, Fungal; Female; Histone Deacetylase Inhibitors; Human Umbilical Vein Endothelial Cells; Humans; Mice; Mice, Inbred ICR; Sterol 14-Demethylase; Treatment Outcome | 2020 |
Surveillance Study of Epidemiology, Antifungal Susceptibility and Risk Factors of Invasive Candidiasis in Critically ill Patients.
Topics: Amphotericin B; Antifungal Agents; Candida; Candidiasis; Candidiasis, Invasive; Critical Illness; Drug Resistance, Fungal; Fluconazole; Flucytosine; Humans; Itraconazole; Microbial Sensitivity Tests; Risk Factors; Voriconazole | 2022 |
Clinical azole cross-resistance in Candida parapsilosis is related to a novel MRR1 gain-of-function mutation.
Topics: Antifungal Agents; Azoles; Candida parapsilosis; Candidiasis; Drug Resistance, Fungal; Fluconazole; Fungal Proteins; Gain of Function Mutation; Microbial Sensitivity Tests; Mutation; Voriconazole | 2022 |
A longitudinal study of Candida bloodstream infections in a Japanese university hospital: species distribution, drug susceptibility, clinical features, and mortality predictors.
Topics: Amphotericin B; Antifungal Agents; Candida; Candida glabrata; Candidemia; Candidiasis; Drug Resistance, Fungal; Fluconazole; Hospitals, University; Humans; Japan; Longitudinal Studies; Micafungin; Microbial Sensitivity Tests; Retrospective Studies; Voriconazole | 2022 |
Fungal esophagitis associated with tuberculous pericarditis in an human immunodeficiency virus-positive patient: a case report.
Topics: Adult; Antifungal Agents; Candidiasis; Esophagitis; Fluconazole; HIV; Humans; Male; Mycoses; Pericarditis, Tuberculous; Voriconazole | 2022 |
Impact of COVID-19 pandemic on antifungal consumption: a multicenter retrospective analysis.
Topics: Antifungal Agents; Candidiasis; Caspofungin; COVID-19; Humans; Intensive Care Units; Pandemics; Retrospective Studies; Voriconazole | 2022 |
Galleria mellonella as an alternative in vivo model to study implant-associated fungal infections.
Topics: Amphotericin B; Animals; Antifungal Agents; Biofilms; Candida albicans; Candidiasis; Fluconazole; Humans; Larva; Mammals; Microbial Sensitivity Tests; Voriconazole | 2023 |
Alarming Increase of Azole-Resistant Candida Causing Blood Stream Infections in Oncology Patients in Egypt.
Topics: Antifungal Agents; Azoles; Candida; Candida albicans; Candidemia; Candidiasis; Drug Resistance, Fungal; Egypt; Fluconazole; Humans; Microbial Sensitivity Tests; Neoplasms; Voriconazole | 2023 |
Analysis of global antifungal surveillance results reveals predominance of Erg11 Y132F alteration among azole-resistant Candida parapsilosis and Candida tropicalis and country-specific isolate dissemination.
Topics: Amino Acid Substitution; Amphotericin B; Antifungal Agents; Azoles; Candida albicans; Candida parapsilosis; Candida tropicalis; Candidiasis; Candidiasis, Invasive; Drug Resistance, Fungal; Echinocandins; Fluconazole; Humans; Microbial Sensitivity Tests; Sterol 14-Demethylase; Voriconazole | 2020 |
Acquisition of FKS2 mutation after echinocandin treatment of infective endocarditis by Candida glabrata.
Topics: Aged; Anidulafungin; Antifungal Agents; Candida glabrata; Candidemia; Candidiasis; Endocarditis; Female; Fungal Proteins; Heart Valve Prosthesis Implantation; Humans; Microbial Sensitivity Tests; Point Mutation; Voriconazole | 2019 |
Candida auris in various hospitals across Kuwait and their susceptibility and molecular basis of resistance to antifungal drugs.
Topics: Antifungal Agents; Candida; Candidemia; Candidiasis; Cross Infection; Drug Resistance, Fungal; Fluconazole; Genes, Fungal; Humans; Kuwait; Micafungin; Microbial Sensitivity Tests; Pathology, Molecular; Voriconazole | 2020 |
Necessity to identify candida species accurately with minimum inhibitory concentration determination in each case of bloodstream infections.
Topics: Amphotericin B; Antifungal Agents; Bacteremia; Candida; Candida tropicalis; Candidiasis; Caspofungin; Cross-Sectional Studies; Fluconazole; Humans; Intensive Care Units; Microbial Sensitivity Tests; Polymerase Chain Reaction; Polymorphism, Restriction Fragment Length; Voriconazole | 2020 |
Azole resistance in Candida from animals calls for the One Health approach to tackle the emergence of antimicrobial resistance.
Topics: Animals; Antifungal Agents; Candida albicans; Candida parapsilosis; Candida tropicalis; Candidiasis; Drug Resistance, Fungal; Female; Fluconazole; Humans; Itraconazole; Male; Voriconazole | 2020 |
Case Report: Beyond the Blood-retina Barrier: Intravitreal Caspofungin for Fungal Endophthalmitis.
Topics: Adult; Aged; Amphotericin B; Antifungal Agents; Aspergillosis; Aspergillus; Blood-Retinal Barrier; Candida; Candidiasis; Caspofungin; Endophthalmitis; Eye Infections, Fungal; Humans; Intravitreal Injections; Male; Visual Acuity; Vitrectomy; Voriconazole | 2020 |
Case report: Candida krusei spondylitis in an immunocompromised patient.
Topics: Aged; Anidulafungin; Antifungal Agents; Candida; Candidemia; Candidiasis; Humans; Immunocompromised Host; Induction Chemotherapy; Male; Micafungin; Spondylitis; Treatment Outcome; Voriconazole | 2020 |
Topics: Antifungal Agents; Azoles; Candida albicans; Candida tropicalis; Candidiasis; Drug Resistance, Fungal; Ergosterol; Fluconazole; Fungal Proteins; Humans; Microbial Sensitivity Tests; Permeability; Voriconazole | 2020 |
Case Report: Endogenous Candida Endophthalmitis in Cornelia de Lange Syndrome: Atypical Stellate Neuroretinitis.
Topics: Administration, Ophthalmic; Amphotericin B; Antifungal Agents; Bacteremia; Candida albicans; Candidemia; Candidiasis; Child, Preschool; De Lange Syndrome; Endophthalmitis; Eye Infections, Fungal; Female; Humans; Intravitreal Injections; Klebsiella; Klebsiella Infections; Retinitis; Voriconazole | 2021 |
Post COVID-19 opportunistic candida retinitis: A case report.
Topics: Administration, Oral; Adult; Antifungal Agents; Candidiasis; COVID-19; Eye Infections, Fungal; Fluconazole; Humans; Intravitreal Injections; Male; Opportunistic Infections; Retinitis; SARS-CoV-2; Tomography, Optical Coherence; Visual Acuity; Voriconazole | 2021 |
Interface Drainage and Antimicrobial Irrigation Avoid Repeat Keratoplasty for Post-DSAEK Cold Interface Abscess.
Topics: Abscess; Aged; Antifungal Agents; Candidiasis; Corneal Ulcer; Descemet Stripping Endothelial Keratoplasty; Eye Infections, Fungal; Female; Humans; Reoperation; Retrospective Studies; Suction; Therapeutic Irrigation; Voriconazole | 2021 |
Chronic endogenous fungal endophthalmitis: diagnostic and treatment challenges: A case report.
Topics: Antifungal Agents; Candida albicans; Candidiasis; Combined Modality Therapy; Endophthalmitis; Eye Infections, Fungal; Humans; Male; Middle Aged; Vitrectomy; Voriconazole | 2021 |
Axillary Digital Thermometers uplifted a multidrug-susceptible Candida auris outbreak among COVID-19 patients in Brazil.
Topics: Adult; Aged; Aged, 80 and over; Anidulafungin; Antifungal Agents; Brazil; Candida; Candidiasis; COVID-19; Critical Care; Disease Outbreaks; Disease Transmission, Infectious; Female; Fluconazole; Humans; Male; Microbial Sensitivity Tests; Middle Aged; Prevalence; SARS-CoV-2; Thermometers; Voriconazole | 2021 |
Pharmacokinetics of voriconazole and its alteration by Candida albicans infection in silkworms.
Topics: Animals; Antifungal Agents; Bombyx; Candida albicans; Candidiasis; Disease Models, Animal; Hemolymph; Voriconazole | 2021 |
Successful, Combined Long-term Treatment of Cerebral Candidiasis and Aspergillosis in a Liver Transplant Recipient: A Case Report.
Topics: Antifungal Agents; Aspergillosis; Candidiasis; Humans; Liver Transplantation; Voriconazole | 2021 |
Distribution and antifungal susceptibility of yeasts isolates from intensive care unit patients.
Topics: Amphotericin B; Antifungal Agents; Candida; Candidiasis; Drug Resistance, Fungal; Fluconazole; Humans; Intensive Care Units; Microbial Sensitivity Tests; Voriconazole | 2017 |
The Effectiveness of Voriconazole in Therapy of Candida glabrata's Biofilms Oral Infections and Its Influence on the Matrix Composition and Gene Expression.
Topics: Antifungal Agents; Biofilms; Candida glabrata; Candidiasis; Extracellular Matrix; Female; Gene Expression Profiling; Gene Expression Regulation, Fungal; Humans; Real-Time Polymerase Chain Reaction; Urinary Tract; Vagina; Voriconazole | 2017 |
Candidiasis: Prevalence and resistance profiling in a tertiary care hospital of Pakistan.
Topics: Amphotericin B; Antifungal Agents; Candida albicans; Candida glabrata; Candidiasis; Cross-Sectional Studies; Drug Resistance, Fungal; Fluconazole; Humans; Ketoconazole; Kidney Failure, Chronic; Kidney Transplantation; Microbial Sensitivity Tests; Pakistan; Prevalence; Prospective Studies; Tertiary Care Centers; Voriconazole | 2017 |
Cross-resistance between voriconazole and fluconazole for non-albicans Candida infection: a case-case-control study.
Topics: Aged; Antifungal Agents; Antimicrobial Stewardship; Candida; Candidiasis; Case-Control Studies; China; Drug Resistance, Multiple, Fungal; Female; Fluconazole; Humans; Male; Microbial Sensitivity Tests; Middle Aged; Risk Factors; Voriconazole | 2017 |
Prevalence and antifungal susceptibility of Candida species in a tertiary care hospital in Islamabad, Pakistan.
Topics: Adolescent; Adult; Amphotericin B; Antifungal Agents; Candida; Candida albicans; Candida glabrata; Candida parapsilosis; Candida tropicalis; Candidiasis; Candidiasis, Vulvovaginal; Child; Child, Preschool; Cross-Sectional Studies; Drug Resistance, Fungal; Female; Fluconazole; Humans; Infant; Infant, Newborn; Inpatients; Male; Microbial Sensitivity Tests; Middle Aged; Molecular Epidemiology; Outpatients; Pakistan; Prevalence; Prospective Studies; Respiratory Tract Infections; Tertiary Care Centers; Urinary Tract Infections; Voriconazole; Young Adult | 2017 |
The identification of Meyerozyma guilliermondii from blood cultures and surveillance samples in a university hospital in Northeast Turkey: A ten-year survey.
Topics: Antifungal Agents; Blood Culture; Candida; Candidiasis; Drug Resistance, Fungal; Epidemiological Monitoring; Fluconazole; Hospitalization; Hospitals, University; Humans; Intensive Care Units; Itraconazole; Microbial Sensitivity Tests; Mycoses; Pichia; Surveys and Questionnaires; Time Factors; Turkey; Voriconazole | 2017 |
Comparative genomic and transcriptomic analyses unveil novel features of azole resistance and adaptation to the human host in Candida glabrata.
Topics: Alleles; Antifungal Agents; Candida glabrata; Candidiasis; Computational Biology; Drug Resistance, Fungal; Fluconazole; Gene Deletion; Gene Expression Profiling; Gene Expression Regulation, Fungal; Gene Frequency; Genome, Fungal; Genomics; Host-Pathogen Interactions; Humans; Molecular Sequence Annotation; Transcriptome; Voriconazole | 2018 |
Identification and antifungal susceptibility of Candida species isolated from the urine of patients in a university hospital in Brazil.
Topics: Adult; Aged; Aged, 80 and over; Amphotericin B; Antifungal Agents; Brazil; Candida; Candidiasis; Drug Resistance, Fungal; Electrophoresis, Agar Gel; Female; Fluconazole; Hospitals, University; Humans; Male; Microbial Sensitivity Tests; Middle Aged; Random Amplified Polymorphic DNA Technique; Treatment Outcome; Urinary Tract Infections; Voriconazole; Young Adult | 2017 |
Candida infanticola and Candida spencermartinsiae yeasts: Possible emerging species in cancer patients.
Topics: Adolescent; Antifungal Agents; Candida; Candidiasis; Caspofungin; Child, Preschool; Echinocandins; Fluconazole; Humans; Kluyveromyces; Lipopeptides; Male; Microbial Sensitivity Tests; Middle Aged; Neoplasms; Nitriles; Opportunistic Infections; Pichia; Pyridines; Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization; Triazoles; Voriconazole | 2018 |
Optimization of Voriconazole Therapy for the Treatment of Invasive Fungal Infections in Adults.
Topics: Adult; Aged; Antifungal Agents; Aspergillosis; Aspergillus; Candida; Candidiasis; Cytochrome P-450 CYP2C19; Drug Dosage Calculations; Drug Interactions; Drug Monitoring; Female; Genotype; Humans; Invasive Fungal Infections; Male; Microbial Sensitivity Tests; Middle Aged; Models, Biological; Pantoprazole; Pharmacogenomic Variants; Phenotype; Proton Pump Inhibitors; Risk Assessment; Voriconazole | 2018 |
Comparative Study of the Effects of Fluconazole and Voriconazole on Candida glabrata, Candida parapsilosis and Candida rugosa Biofilms.
Topics: Antifungal Agents; Biofilms; Candida; Candidiasis; Fluconazole; Humans; Microbial Sensitivity Tests; Microbial Viability; Microscopy, Electron, Scanning; Microscopy, Electron, Transmission; Voriconazole | 2018 |
Anti-candidal activity of selected analgesic drugs used alone and in combination with fluconazole, itraconazole, voriconazole, posaconazole and isavuconazole.
Topics: Acetaminophen; Analgesics; Antifungal Agents; Aspirin; Candida; Candida albicans; Candida glabrata; Candidiasis; Dipyrone; Drug Resistance, Fungal; Fluconazole; Humans; Ibuprofen; Itraconazole; Meloxicam; Microbial Sensitivity Tests; Nitriles; Pyridines; Triazoles; Voriconazole | 2018 |
Voriconazole Treatment for an Infant With Intractable Candida glabrata Meningitis.
Topics: Administration, Intravenous; Antifungal Agents; Candida glabrata; Candidiasis; Drug Resistance, Fungal; Drug Therapy, Combination; Fatal Outcome; Humans; Infant; Infant, Premature; Male; Meningitis; Microbial Sensitivity Tests; Multiple Organ Failure; Voriconazole | 2018 |
Relevance of antifungal penetration in biofilm-associated resistance of Candida albicans and non-albicans Candida species.
Topics: Amphotericin B; Antifungal Agents; Biofilms; Candida; Candida albicans; Candidiasis; Drug Resistance, Fungal; Humans; Voriconazole | 2018 |
Management of
Topics: Administration, Oral; Adult; Antifungal Agents; Candida glabrata; Candidiasis; Cornea; Drug Therapy, Combination; Endophthalmitis; Eye Infections, Fungal; Glucocorticoids; Humans; Keratitis; Keratoconus; Keratoplasty, Penetrating; Male; Ophthalmic Solutions; Prednisolone; Surgical Wound Infection; Voriconazole | 2018 |
Synergistic interactions of sulfamethoxazole and azole antifungal drugs against emerging multidrug-resistant Candida auris.
Topics: Animals; Antifungal Agents; Caenorhabditis elegans; Candida; Candidiasis; Disease Models, Animal; Drug Synergism; Itraconazole; Sulfamethoxazole; Survival Analysis; Treatment Outcome; Voriconazole | 2018 |
Impact of Iontophoresis and PACK-CXL Corneal Concentrations of Antifungals in an In Vivo Model.
Topics: Animals; Antifungal Agents; Candida albicans; Candidiasis; Collagen; Cornea; Cross-Linking Reagents; Disease Models, Animal; Eye Infections, Fungal; Fusariosis; Fusarium; Iontophoresis; Keratitis; Photochemotherapy; Rabbits; Ultraviolet Rays; Voriconazole | 2018 |
Clinical Significance of the Floral Shift in Candidiasis.
Topics: Amphotericin B; Antifungal Agents; Azoles; Candida; Candida albicans; Candidiasis; Caspofungin; Drug Resistance, Fungal; Fluconazole; Humans; Nystatin; Oils, Volatile; Voriconazole | 2018 |
Interaction of carvacroland voriconazole against drug - resistant Candida strains isolated from patients with candidiasis.
Topics: Antifungal Agents; Candida; Candidiasis; Cymenes; Drug Resistance, Fungal; Humans; Microbial Sensitivity Tests; Monoterpenes; Voriconazole | 2019 |
Vacuolar proton-translocating ATPase is required for antifungal resistance and virulence of Candida glabrata.
Topics: Animals; Antifungal Agents; Candida glabrata; Candidiasis; Drug Resistance, Fungal; Drug Resistance, Multiple, Fungal; Drug Synergism; Female; Fluconazole; Fungal Proteins; Gene Deletion; Genes, Fungal; Humans; Macrolides; Mice; Mice, Inbred BALB C; Vacuolar Proton-Translocating ATPases; Vacuoles; Virulence; Voriconazole | 2019 |
In vitro activity of voriconazole and amphotericin B against Candida albicans, Candida krusei, and Cryptococcus neoformans in human cerebrospinal fluid.
Topics: Amphotericin B; Antifungal Agents; Candida; Candida albicans; Candidiasis; Central Nervous System Infections; Cerebrospinal Fluid; Cryptococcosis; Cryptococcus neoformans; Humans; Voriconazole | 2019 |
Expression of ERG11 and efflux pump genes CDR1, CDR2 and SNQ2 in voriconazole susceptible and resistant Candida glabrata strains.
Topics: Antifungal Agents; Candida glabrata; Candidiasis; Drug Resistance, Multiple, Fungal; Fungal Proteins; Gene Expression; Membrane Transport Proteins; Microbial Sensitivity Tests; Mutation; Voriconazole | 2020 |
Pharmacokinetic/Pharmacodynamic Analysis of Voriconazole Against Candida spp. and Aspergillus spp. in Allogeneic Stem Cell Transplant Recipients.
Topics: Administration, Oral; Adult; Aged; Allografts; Antifungal Agents; Aspergillosis; Aspergillus; Candida; Candidiasis; Dose-Response Relationship, Drug; Female; Humans; Male; Middle Aged; Monte Carlo Method; Stem Cell Transplantation; Voriconazole | 2019 |
Amphotericin B Induction with Voriconazole Consolidation as Salvage Therapy for
Topics: Amphotericin B; Antifungal Agents; Arthritis, Infectious; Candida glabrata; Candidiasis; Drug Resistance, Fungal; Echinocandins; Fungal Proteins; Humans; Middle Aged; Osteomyelitis; Salvage Therapy; Voriconazole | 2019 |
Native aortic valve fungal endocarditis.
Topics: Administration, Oral; Adult; Antifungal Agents; Aortic Valve; Candida albicans; Candidiasis; Diagnosis, Differential; Echocardiography, Transesophageal; Endocarditis; Follow-Up Studies; Heart Valve Diseases; Humans; Male; Pyrimidines; Tomography, X-Ray Computed; Triazoles; Voriconazole | 2013 |
Voriconazole therapeutic drug monitoring: retrospective cohort study of the relationship to clinical outcomes and adverse events.
Topics: Adult; Antifungal Agents; Brain Diseases, Metabolic; Candidiasis; Drug Administration Schedule; Drug Monitoring; Female; Hematologic Neoplasms; Hematopoietic Stem Cell Transplantation; Humans; Liver; Male; Middle Aged; Pulmonary Aspergillosis; Pyrimidines; Retrospective Studies; Treatment Outcome; Triazoles; Voriconazole | 2013 |
Antifungal efficacy during Candida krusei infection in non-conventional models correlates with the yeast in vitro susceptibility profile.
Topics: Amphotericin B; Animals; Antifungal Agents; Caenorhabditis elegans; Candida; Candidiasis; Fluconazole; Lepidoptera; Pyrimidines; Triazoles; Voriconazole | 2013 |
Candida krusei arthritis in an adolescent with acute myelogenous leukemia.
Topics: Adolescent; Antifungal Agents; Arthritis, Infectious; Candida; Candidiasis; Female; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Pyrimidines; Triazoles; Voriconazole | 2013 |
Molecular mechanisms of drug resistance in clinical Candida species isolated from Tunisian hospitals.
Topics: Amino Acid Sequence; Amino Acid Substitution; Amphotericin B; Antifungal Agents; ATP Binding Cassette Transporter, Subfamily B, Member 1; Azoles; Base Sequence; Candida albicans; Candida glabrata; Candida tropicalis; Candidiasis; Cytochrome P-450 Enzyme System; Drug Resistance, Fungal; Ergosterol; Fluconazole; Fungal Proteins; Humans; Microbial Sensitivity Tests; Molecular Sequence Data; Mutation; Polyenes; Pyrimidines; Saccharomyces cerevisiae; Saccharomyces cerevisiae Proteins; Sequence Analysis, DNA; Triazoles; Tunisia; Voriconazole | 2013 |
In vitro fluconazole and voriconazole susceptibilities of Candida bloodstream isolates in Korea: use of the CLSI and EUCAST epidemiological cutoff values.
Topics: Antifungal Agents; Candida; Candidiasis; Drug Resistance, Fungal; Fluconazole; Humans; Microbial Sensitivity Tests; Pyrimidines; Republic of Korea; Triazoles; Voriconazole | 2013 |
Candida urinary tract infection and Candida species susceptibilities to antifungal agents.
Topics: Antifungal Agents; Candida; Candida albicans; Candidiasis; Female; Fluconazole; Flucytosine; Hospitals, University; Humans; Intensive Care Units; Male; Microbial Sensitivity Tests; Pyrimidines; Retrospective Studies; Risk Factors; Triazoles; Urinary Tract Infections; Voriconazole | 2013 |
Interaction between caspofungin or voriconazole and cefoperazone-sulbactam or piperacillin-tazobactam by in vitro and in vivo methods.
Topics: Animals; Anti-Bacterial Agents; Antifungal Agents; Bacterial Infections; Candida albicans; Candidiasis; Caspofungin; Cefoperazone; Drug Interactions; Echinocandins; Female; Lipopeptides; Mice; Mice, Inbred BALB C; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Pyrimidines; Sulbactam; Triazoles; Voriconazole | 2014 |
Predictors of invasive fungal infection in pediatric allogeneic hematopoietic SCT recipients.
Topics: Adolescent; Adult; Amphotericin B; Antifungal Agents; Aspergillosis; Candidiasis; Caspofungin; Child; Child, Preschool; Echinocandins; Female; Fusariosis; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Infant; Lipopeptides; Logistic Models; Male; Mycoses; Neutrophils; Prospective Studies; Pyrimidines; Retrospective Studies; Risk; Treatment Outcome; Triazoles; Voriconazole; Young Adult | 2014 |
Molecular identification and antifungal susceptibility of yeast isolates causing fungemia collected in a population-based study in Spain in 2010 and 2011.
Topics: Antifungal Agents; Candida; Candida albicans; Candida glabrata; Candida tropicalis; Candidiasis; Drug Resistance, Fungal; Echinocandins; Fungemia; Humans; Itraconazole; Ketoconazole; Microbial Sensitivity Tests; Pyrimidines; Spain; Triazoles; Voriconazole | 2014 |
Does topical voriconazole trigger dysplastic changes on the ocular surface?
Topics: Administration, Ophthalmic; Aged; Antifungal Agents; Candida; Candidiasis; Cornea; Corneal Diseases; Corneal Opacity; Diagnosis, Differential; Endophthalmitis; Eye Neoplasms; Humans; Injections, Intraocular; Intravitreal Injections; Male; Microscopy, Confocal; Neoplasms, Squamous Cell; Ophthalmic Solutions; Precancerous Conditions; Treatment Outcome; Voriconazole | 2015 |
Candida arteritis occurring in a liver transplant recipient.
Topics: Anidulafungin; Antifungal Agents; Arteritis; Candidiasis; Echinocandins; Fatal Outcome; Graft Rejection; Humans; Liver Transplantation; Male; Middle Aged; Voriconazole | 2014 |
Efficacy and safety of antifungal additives in Optisol-GS corneal storage medium.
Topics: Amphotericin B; Antifungal Agents; Candida albicans; Candida glabrata; Candidiasis; Cell Count; Chondroitin Sulfates; Colony Count, Microbial; Complex Mixtures; Cornea; Culture Media, Serum-Free; Dextrans; Drug Combinations; Drug Contamination; Endothelium, Corneal; Gentamicins; Humans; Microbial Sensitivity Tests; Organ Preservation; Organ Preservation Solutions; Pyrimidines; Tissue Donors; Treatment Outcome; Triazoles; Voriconazole | 2014 |
In vivo and in vitro acquisition of resistance to voriconazole by Candida krusei.
Topics: Adult; Antifungal Agents; Antineoplastic Agents; ATP-Binding Cassette Transporters; Candida; Candidiasis; Drug Resistance, Fungal; Fluconazole; Fungal Proteins; Gene Expression; Humans; Male; Mutation; Opportunistic Infections; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Sterol 14-Demethylase; Tacrolimus; Voriconazole | 2014 |
Intrastromal antifungal injection with secondary lamellar interface infusion for late-onset infectious keratitis after DSAEK.
Topics: Administration, Oral; Aged; Amphotericin B; Antifungal Agents; Candidiasis; Corneal Stroma; Corneal Ulcer; Descemet Stripping Endothelial Keratoplasty; Eye Infections, Fungal; Fluconazole; Humans; Infusions, Intralesional; Injections, Intraocular; Male; Microscopy, Confocal; Voriconazole | 2014 |
[Post-operative endophthalmitis due to Candida parapsilosis].
Topics: Aged; Anti-Bacterial Agents; Anti-Inflammatory Agents; Antifungal Agents; Antihypertensive Agents; Candidiasis; Cataract Extraction; Drug Therapy, Combination; Endophthalmitis; Eye Infections, Fungal; Female; Humans; Macular Edema; Recurrence; Surgical Wound Infection; Vitrectomy; Voriconazole | 2015 |
[Treatment recommendations for invasive fungal disease in pediatric patients with cancer or blood disease].
Topics: Antifungal Agents; Candidiasis; Caspofungin; Child; Echinocandins; Hematologic Diseases; Humans; Lipopeptides; Mycoses; Neoplasms; Pediatrics; Practice Guidelines as Topic; Voriconazole | 2014 |
Contribution of clinically derived mutations in ERG11 to azole resistance in Candida albicans.
Topics: 14-alpha Demethylase Inhibitors; Amino Acid Substitution; Antifungal Agents; Azoles; Candida albicans; Candidiasis; Catalytic Domain; Drug Resistance, Fungal; Fluconazole; Humans; Itraconazole; Microbial Sensitivity Tests; Molecular Sequence Data; Sterol 14-Demethylase; Voriconazole | 2015 |
Candidemia-induced pediatric sepsis and its association with free radicals, nitric oxide, and cytokine level in host.
Topics: Adolescent; Amphotericin B; Antifungal Agents; Candida; Candidemia; Candidiasis; Child; Child, Preschool; Cross Infection; Cytokines; Female; Fluconazole; Free Radicals; Humans; Incidence; India; Infant; Infant, Newborn; Intensive Care Units; Interleukin-10; Interleukin-1beta; Male; Microbial Sensitivity Tests; Nitric Oxide; Nitric Oxide Synthase; Sepsis; Tumor Necrosis Factor-alpha; Voriconazole | 2015 |
Comparative antifungal susceptibility analysis of Candida albicans versus non-albicans Candida corneal isolates.
Topics: Amphotericin B; Antifungal Agents; Candida; Candida albicans; Candidiasis; Corneal Ulcer; Eye Infections, Fungal; Fluconazole; Humans; Microbial Sensitivity Tests; Natamycin; Voriconazole | 2015 |
Antifungal activity of amphotericin B and voriconazole against the biofilms and biofilm-dispersed cells of Candida albicans employing a newly developed in vitro pharmacokinetic model.
Topics: Amphotericin B; Antifungal Agents; Biofilms; Candida albicans; Candidiasis; Humans; Microbial Sensitivity Tests; Voriconazole | 2015 |
Voriconazole-induced multiple squamous cell carcinomas in a patient with chronic lymphocytic leukemia.
Topics: Aged; Antifungal Agents; Candidiasis; Carcinoma, Squamous Cell; Fatal Outcome; Head and Neck Neoplasms; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Scalp; Skin Neoplasms; Voriconazole | 2015 |
Candida Surveillance in Surgical Intensive Care Unit (SICU) in a Tertiary Institution.
Topics: Adult; Aged; Aged, 80 and over; Amphotericin B; Anidulafungin; Antifungal Agents; beta-Glucans; Candida; Candida albicans; Candida glabrata; Candidiasis; Candidiasis, Invasive; Carrier State; Caspofungin; Critical Care; Echinocandins; Female; Fluconazole; Humans; Incidence; Intensive Care Units; Lipopeptides; Male; Micafungin; Microbial Sensitivity Tests; Middle Aged; Sensitivity and Specificity; Singapore; Tertiary Care Centers; Voriconazole | 2015 |
Evaluation of paper gradient concentration strips for antifungal combination testing of Candida spp.
Topics: Amphotericin B; Antifungal Agents; Azoles; Candida; Candidiasis; Caspofungin; Chi-Square Distribution; Drug Synergism; Drug Therapy, Combination; Echinocandins; Humans; Lipopeptides; Microbial Sensitivity Tests; Reagent Kits, Diagnostic; Reproducibility of Results; Voriconazole | 2015 |
Successful medical treatment of infective endocarditis caused by Candida parapsilosis in an immunocompromised patient.
Topics: Adult; Anidulafungin; Antifungal Agents; Aorta; Candida; Candidiasis; Cross Infection; Echinocandins; Echocardiography; Endocarditis; Female; Humans; Immunocompromised Host; Ovarian Neoplasms; Voriconazole | 2015 |
Voriconazole and posaconazole therapy for experimental Candida lusitaniae infection.
Topics: Animals; Antifungal Agents; beta-Glucans; Candida; Candidiasis; Colony Count, Microbial; Disease Models, Animal; Dose-Response Relationship, Drug; Humans; Kidney; Male; Mice; Proteoglycans; Treatment Outcome; Triazoles; Voriconazole | 2016 |
Activity of Isavuconazole and Other Azoles against Candida Clinical Isolates and Yeast Model Systems with Known Azole Resistance Mechanisms.
Topics: Alleles; Antifungal Agents; ATP Binding Cassette Transporter, Subfamily B, Member 1; Candida albicans; Candida glabrata; Candidiasis; Cytochrome P-450 Enzyme System; Drug Resistance, Fungal; Fluconazole; Fungal Proteins; Gene Expression Regulation, Fungal; Humans; Itraconazole; Membrane Transport Proteins; Microbial Sensitivity Tests; Mutation; Nitriles; Protein Isoforms; Pyridines; Saccharomyces cerevisiae; Saccharomyces cerevisiae Proteins; Triazoles; Voriconazole | 2016 |
Bioassay for Determining Voriconazole Serum Levels in Patients Receiving Combination Therapy with Echinocandins.
Topics: Antifungal Agents; Biological Assay; Candida; Candidiasis; Chromatography, High Pressure Liquid; Colony Count, Microbial; Drug Therapy, Combination; Echinocandins; Humans; Quality Control; Regression Analysis; Reproducibility of Results; Sensitivity and Specificity; Voriconazole | 2016 |
The isolation of Candida rugosa and Candida mesorugosa from clinical samples in Ghana.
Topics: Antifungal Agents; Candida; Candidiasis; Cluster Analysis; DNA, Fungal; DNA, Ribosomal Spacer; Fluconazole; Ghana; Humans; Itraconazole; Microbial Sensitivity Tests; Microbiological Techniques; Phylogeny; Sequence Analysis, DNA; Temperature; Voriconazole | 2016 |
[Species distribution and antifungal susceptibility of Candida spp. causing superficial mycosis. Coro, Falcon state, Venezuela].
Topics: Antifungal Agents; Candida; Candidiasis; Drug Resistance, Fungal; Fluconazole; Humans; Microbial Sensitivity Tests; Nail Diseases; Venezuela; Voriconazole | 2015 |
Sustained Nitric Oxide-Releasing Nanoparticles Induce Cell Death in Candida albicans Yeast and Hyphal Cells, Preventing Biofilm Formation In Vitro and in a Rodent Central Venous Catheter Model.
Topics: Animals; Antifungal Agents; Apoptosis; Biofilms; Candida albicans; Candidiasis; Catheter-Related Infections; Catheterization, Central Venous; Chitosan; Disease Models, Animal; Drug Therapy, Combination; Female; Fluconazole; Fungal Polysaccharides; Hyphae; Microbial Sensitivity Tests; Microbial Viability; Nanoparticles; Nitric Oxide; Nitric Oxide Donors; Organosilicon Compounds; Oxidation-Reduction; Rats; Rats, Sprague-Dawley; Sodium Nitrite; Voriconazole | 2016 |
Voriconazole minimum inhibitory concentrations are predictive of treatment outcome in experimental murine infections by Candida glabrata.
Topics: Animals; Antifungal Agents; Candida glabrata; Candidiasis; Colony Count, Microbial; Disease Models, Animal; Kidney; Male; Mice; Microbial Sensitivity Tests; Treatment Outcome; Voriconazole | 2016 |
Pharmacokinetic/pharmacodynamic analysis of voriconazole against Candida spp. and Aspergillus spp. in children, adolescents and adults by Monte Carlo simulation.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antifungal Agents; Aspergillosis; Candidiasis; Child; Child, Preschool; Female; Humans; Male; Microbial Sensitivity Tests; Middle Aged; Monte Carlo Method; Voriconazole; Young Adult | 2016 |
Identification and antifungal susceptibility of Candida species isolated from bloodstream infections in Konya, Turkey.
Topics: Amphotericin B; Anidulafungin; Antifungal Agents; Candida; Candida albicans; Candidiasis; Caspofungin; Echinocandins; Fluconazole; Humans; Lipopeptides; Microbial Sensitivity Tests; Species Specificity; Triazoles; Voriconazole | 2016 |
A Comparative Study of the Effects of Intravitreal Anidulafungin, Voriconazole, and Amphotericin B in an Experimental Candida Endophthalmitis Model.
Topics: Amphotericin B; Anidulafungin; Animals; Antifungal Agents; Candida albicans; Candidiasis; Conjunctiva; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Therapy, Combination; Echinocandins; Endophthalmitis; Eye Infections, Fungal; Intravitreal Injections; Iris; Male; Rabbits; Vitreous Body; Voriconazole | 2017 |
Species distribution & antifungal susceptibility pattern of oropharyngeal Candida isolates from human immunodeficiency virus infected individuals.
Topics: Adolescent; Adult; Aged; Antiretroviral Therapy, Highly Active; Candida; Candidiasis; Child; Child, Preschool; Disk Diffusion Antimicrobial Tests; Drug Resistance, Fungal; Female; Fluconazole; HIV; HIV Infections; HIV Seropositivity; Humans; Male; Middle Aged; Oropharynx; Voriconazole | 2016 |
Expression Patterns of ABC Transporter Genes in Fluconazole-Resistant Candida glabrata.
Topics: Amino Acid Substitution; Antifungal Agents; ATP-Binding Cassette Transporters; Candida glabrata; Candidiasis; Drug Resistance, Fungal; Fluconazole; Gene Expression Profiling; Humans; Iran; Itraconazole; Microbial Sensitivity Tests; Mutation, Missense; Real-Time Polymerase Chain Reaction; Sequence Analysis, DNA; Voriconazole | 2017 |
Invasive Aspergillosis of the Stomach and Co-infection With Candida krusei in a Patient With Terminal Liver Failure: A Case Report.
Topics: Antifungal Agents; Aspergillosis; Candidiasis; Caspofungin; Coinfection; Echinocandins; End Stage Liver Disease; Gastric Mucosa; Humans; Lipopeptides; Liver Transplantation; Stomach Diseases; Voriconazole | 2016 |
Mutations and/or Overexpressions of ERG4 and ERG11 Genes in Clinical Azoles-Resistant Isolates of Candida albicans.
Topics: Amphotericin B; Antifungal Agents; Candida albicans; Candidiasis; Cytochrome P-450 Enzyme System; Drug Resistance, Fungal; Fluconazole; Flucytosine; Fungal Proteins; Gene Expression; Humans; Itraconazole; Microbial Sensitivity Tests; Mutation; Oxidoreductases; RNA, Messenger; Sequence Analysis, DNA; Voriconazole | 2017 |
Synergistic Effects of Tetrandrine with Posaconazole Against Aspergillus fumigatus.
Topics: Animals; Antifungal Agents; Aspergillosis; Aspergillus fumigatus; Benzylisoquinolines; Candidiasis; Drug Resistance, Fungal; Drug Synergism; Female; Humans; Itraconazole; Mice; Mice, Inbred BALB C; Microbial Sensitivity Tests; Triazoles; Voriconazole | 2017 |
Invasive Candida krusei infection and Candida vasculitis of a leg ulcer in an immunocompetent patient: A case report.
Topics: Aged; Antifungal Agents; Biopsy; Candida; Candidiasis; Female; Humans; Leg Ulcer; Vasculitis; Voriconazole; Wound Healing | 2017 |
Trends in species distribution and susceptibility of bloodstream isolates of Candida collected in Monterrey, Mexico, to seven antifungal agents: results of a 3-year (2004 to 2007) surveillance study.
Topics: Adolescent; Adult; Age Factors; Aged; Aged, 80 and over; Amphotericin B; Antifungal Agents; Candida; Candida albicans; Candida glabrata; Candida tropicalis; Candidiasis; Caspofungin; Child; Child, Preschool; Echinocandins; Female; Fluconazole; Humans; Infant; Infant, Newborn; Itraconazole; Lipopeptides; Male; Mexico; Microbial Sensitivity Tests; Middle Aged; Pyrimidines; Thiazoles; Triazoles; Voriconazole; Young Adult | 2008 |
Candida spp. in vitro susceptibility profile to four antifungal agents. Resistance surveillance study in Venezuelan strains.
Topics: Adolescent; Adult; Amphotericin B; Antifungal Agents; Azoles; Candida; Candida albicans; Candidiasis; Child; Child, Preschool; Drug Resistance, Fungal; Female; Fluconazole; Humans; Infant; Itraconazole; Male; Microbial Sensitivity Tests; Middle Aged; Population Surveillance; Pyrimidines; Triazoles; Venezuela; Voriconazole; Young Adult | 2009 |
Comparison of posaconazole and voriconazole in vitro killing against Candida krusei.
Topics: Antifungal Agents; Candida; Candidiasis; Culture Media; Drug Resistance, Fungal; Fungemia; Humans; Microbial Sensitivity Tests; Pyrimidines; Time Factors; Triazoles; Voriconazole | 2008 |
Activity of voriconazole, itraconazole, fluconazole and amphotericin B in vitro against 1763 yeasts from 472 patients in the voriconazole phase III clinical studies.
Topics: Amphotericin B; Antifungal Agents; Candida; Candidiasis; Clinical Trials, Phase III as Topic; Fluconazole; Humans; Itraconazole; Microbial Sensitivity Tests; Mycoses; Pyrimidines; Triazoles; Voriconazole; Yeasts | 2008 |
Voriconazole-induced photosensitivity.
Topics: Antifungal Agents; Candidiasis; Endocarditis; Humans; Male; Middle Aged; Photosensitivity Disorders; Pyrimidines; Triazoles; Voriconazole | 2008 |
National surveillance of antifungal susceptibility of Candida species in South Korean hospitals.
Topics: Antifungal Agents; Candida; Candidiasis; Drug Resistance, Fungal; Fluconazole; Flucytosine; Hospitals; Humans; Microbial Sensitivity Tests; Population Surveillance; Pyrimidines; Republic of Korea; Triazoles; Voriconazole | 2009 |
Efficacy of isavuconazole, voriconazole and fluconazole in temporarily neutropenic murine models of disseminated Candida tropicalis and Candida krusei.
Topics: Animals; Antifungal Agents; Brain; Candidiasis; Colony Count, Microbial; Dose-Response Relationship, Drug; Fluconazole; Kidney; Male; Mice; Neutropenia; Nitriles; Pyridines; Pyrimidines; Treatment Outcome; Triazoles; Voriconazole | 2009 |
Free renal levels of voriconazole determined by microdialysis in healthy and Candida sp.-infected Wistar rats.
Topics: Animals; Antifungal Agents; Area Under Curve; Candidiasis; Kidney; Male; Microdialysis; Models, Animal; Protein Binding; Pyrimidines; Rats; Rats, Wistar; Serum; Triazoles; Voriconazole | 2009 |
A global evaluation of voriconazole activity tested against recent clinical isolates of Candida spp.
Topics: Antifungal Agents; Candida; Candidiasis; Drug Resistance, Fungal; Global Health; Humans; Microbial Sensitivity Tests; Population Surveillance; Pyrimidines; Triazoles; Voriconazole | 2009 |
Susceptibility to voriconazole, fluconazole, and ketoconazole of yeast isolated from patients with hematological malignancies.
Topics: Antifungal Agents; Candida; Candidiasis; Drug Resistance, Fungal; Fluconazole; Hematologic Neoplasms; Humans; Ketoconazole; Microbial Sensitivity Tests; Pyrimidines; Triazoles; Voriconazole | 2008 |
In vitro activity of caspofungin and voriconazole against uncommon Candida spp.
Topics: Antifungal Agents; Candida; Candidiasis; Caspofungin; Echinocandins; Humans; Lipopeptides; Microbial Sensitivity Tests; Pyrimidines; Triazoles; Voriconazole | 2009 |
Candida parapsilosis endocarditis in aged patient.
Topics: Aged, 80 and over; Antifungal Agents; Candida; Candidiasis; Drug Therapy, Combination; Endocarditis; Female; Fluconazole; Humans; Pyrimidines; Triazoles; Voriconazole | 2009 |
In vitro antifungal combination effects of micafungin with fluconazole, voriconazole, amphotericin B, and flucytosine against clinical isolates of Candida species.
Topics: Amphotericin B; Antifungal Agents; Candida; Candidiasis; Drug Synergism; Echinocandins; Fluconazole; Flucytosine; Humans; Lipopeptides; Micafungin; Pyrimidines; Triazoles; Voriconazole | 2009 |
Breakthrough Candida dubliniensis fungemia in an acute myeloid leukemia patient during voriconazole therapy successfully treated with caspofungin.
Topics: Adult; Antifungal Agents; Antineoplastic Combined Chemotherapy Protocols; Candida; Candidiasis; Caspofungin; Catheter-Related Infections; Cross Infection; Echinocandins; Fungemia; Humans; Leukemia, Myeloid, Acute; Lipopeptides; Male; Opportunistic Infections; Pyrimidines; Triazoles; Voriconazole | 2009 |
Topical and oral voriconazole in the treatment of fungal keratitis.
Topics: Administration, Oral; Antifungal Agents; Candidiasis; Cornea; Diagnosis, Differential; Dose-Response Relationship, Drug; Eye Infections, Fungal; Follow-Up Studies; Humans; Keratitis; Male; Middle Aged; Ophthalmic Solutions; Pyrimidines; Triazoles; Voriconazole | 2009 |
Pharmacokinetic/pharmacodynamic modelling and in vitro simulation of dynamic voriconazole-Candida interactions.
Topics: Administration, Oral; Algorithms; Antifungal Agents; Candida; Candida albicans; Candida glabrata; Candidiasis; Humans; Infusions, Intravenous; Microbial Sensitivity Tests; Models, Theoretical; Pyrimidines; Time Factors; Triazoles; Voriconazole | 2009 |
[Two cases of mycoses associated with hematologic disease].
Topics: Aged; Amphotericin B; Antifungal Agents; Aspergillosis; Candidiasis; Cunninghamella; Fatal Outcome; Humans; Liposomes; Male; Mucormycosis; Myelodysplastic Syndromes; Pyrimidines; Treatment Outcome; Triazoles; Voriconazole | 2008 |
Safe management of tacrolimus together with posaconazole in lung transplant patients with cystic fibrosis.
Topics: Adult; Antifungal Agents; Aspergillosis; Candidiasis; Cystic Fibrosis; Cytochrome P-450 CYP3A; Cytochrome P-450 CYP3A Inhibitors; Drug Interactions; Drug Monitoring; Drug-Related Side Effects and Adverse Reactions; Enzyme Inhibitors; Female; Graft Rejection; Humans; Immunosuppressive Agents; Itraconazole; Lung Transplantation; Male; Microbial Sensitivity Tests; Mycoses; Prescriptions; Pyrimidines; Tacrolimus; Triazoles; Voriconazole | 2009 |
[In vitro activity of voriconazole and other antifungal agents against clinical isolates of 138 Candida spp].
Topics: Amphotericin B; Antifungal Agents; Candida; Candidiasis; Drug Resistance, Fungal; Drug Resistance, Multiple, Fungal; Fluconazole; Flucytosine; Humans; Itraconazole; Microbial Sensitivity Tests; Pyrimidines; Species Specificity; Triazoles; Voriconazole | 2009 |
Reliability of the Vitek 2 yeast susceptibility test for detection of in vitro resistance to fluconazole and voriconazole in clinical isolates of Candida albicans and Candida glabrata.
Topics: Antifungal Agents; Candida albicans; Candida glabrata; Candidiasis; Drug Resistance, Fungal; Fluconazole; Humans; Microbial Sensitivity Tests; Pyrimidines; Sensitivity and Specificity; Triazoles; Voriconazole | 2009 |
[Conservative management with new antifungals in a case of Candida prosthetic valve endocarditis].
Topics: Amphotericin B; Antifungal Agents; Bioprosthesis; Candidiasis; Caspofungin; Drug Therapy, Combination; Echinocandins; Endocarditis; Heart Valve Prosthesis; Humans; Lipopeptides; Liposomes; Male; Middle Aged; Photosensitivity Disorders; Postoperative Complications; Prosthesis-Related Infections; Pyrimidines; Triazoles; Voriconazole | 2010 |
In vitro activities of fluconazole, itraconazole and voriconazole against otomycotic fungal pathogens.
Topics: Antifungal Agents; Aspergillus; Candida albicans; Candidiasis; Colony Count, Microbial; Ear Diseases; Fluconazole; Humans; Itraconazole; Pyrimidines; Treatment Outcome; Triazoles; Voriconazole | 2009 |
Infections caused by Candida krusei in five transplant and two surgical patients.
Topics: Adult; Aged; Antifungal Agents; Candida; Candidiasis; Caspofungin; Cluster Analysis; Cross Infection; DNA Fingerprinting; DNA, Fungal; Echinocandins; Female; Genotype; Humans; Immunocompromised Host; Lipopeptides; Male; Middle Aged; Mycological Typing Techniques; Organ Transplantation; Postoperative Complications; Pyrimidines; Random Amplified Polymorphic DNA Technique; Treatment Outcome; Triazoles; Voriconazole | 2009 |
Therapeutic efficacy of voriconazole against a fluconazole-resistant Candida albicans isolate in a vaginal model.
Topics: Administration, Intravaginal; Administration, Oral; Animals; Antifungal Agents; Candida albicans; Candidiasis; Colony Count, Microbial; Drug Resistance, Fungal; Female; Fluconazole; Mice; Mice, Inbred BALB C; Pyrimidines; Treatment Outcome; Triazoles; Vagina; Voriconazole | 2009 |
Direct antifungal susceptibility testing of positive Candida blood cultures by sensititre YeastOne.
Topics: Amphotericin B; Antifungal Agents; Candida; Candidiasis; Drug Resistance, Fungal; Fluconazole; Flucytosine; Humans; Itraconazole; Ketoconazole; Microbial Sensitivity Tests; Pyrimidines; Reagent Kits, Diagnostic; Sensitivity and Specificity; Time Factors; Triazoles; Voriconazole | 2009 |
Disk diffusion test and E-test with enriched Mueller-Hinton agar for determining susceptibility of Candida species to voriconazole and fluconazole.
Topics: Antifungal Agents; Candida; Candidiasis; Culture Media; Fluconazole; Humans; Microbial Sensitivity Tests; Pyrimidines; Taiwan; Triazoles; Voriconazole | 2009 |
Effects of antifungal agents in sap activity of Candida albicans isolates.
Topics: Antifungal Agents; Aspartic Acid Proteases; Candida albicans; Candidiasis; Culture Media; DNA, Fungal; Drug Resistance, Fungal; Fluconazole; HIV Infections; Humans; Microbial Sensitivity Tests; Mouth Mucosa; Polymerase Chain Reaction; Pyrimidines; Triazoles; Voriconazole | 2010 |
Voriconazole is safe and effective as prophylaxis for early and late fungal infections following allogeneic hematopoietic stem cell transplantation.
Topics: Adolescent; Adult; Aged; Antifungal Agents; Aspergillosis; Candidiasis; Chemoprevention; Female; Hematopoietic Stem Cell Transplantation; Humans; Incidence; Male; Middle Aged; Mycoses; Pyrimidines; Time Factors; Transplantation, Homologous; Triazoles; Voriconazole; Young Adult | 2010 |
Examination of potential virulence factors of Candida tropicalis clinical isolates from hospitalized patients.
Topics: Amphotericin B; Antifungal Agents; Biofilms; Blood; Candida tropicalis; Candidiasis; Catheterization; Cell Adhesion; Cells, Cultured; Enzymes; Epithelial Cells; Equipment and Supplies; Fluconazole; Fungal Proteins; Hemolysin Proteins; Humans; Microbial Sensitivity Tests; Pyrimidines; Triazoles; Urine; Virulence Factors; Voriconazole | 2010 |
Successful use of topical voriconazole 1% alone as first-line antifungal therapy against Candida albicans keratitis.
Topics: Administration, Topical; Antifungal Agents; Candidiasis; Humans; Keratitis; Male; Middle Aged; Ophthalmic Solutions; Pyrimidines; Treatment Outcome; Triazoles; Voriconazole | 2009 |
Antifungal susceptibility of 205 Candida spp. isolated primarily during invasive Candidiasis and comparison of the Vitek 2 system with the CLSI broth microdilution and Etest methods.
Topics: Amphotericin B; Antifungal Agents; Automation; Candida; Candidiasis; Fluconazole; Humans; Intensive Care Units; Microbial Sensitivity Tests; Pyrimidines; Statistics as Topic; Triazoles; Voriconazole | 2010 |
Antifungal susceptibility testing of Candida isolates from the Candida surveillance study.
Topics: Antifungal Agents; Candida; Candidiasis; Cross Infection; Echinocandins; Fluconazole; Humans; Microbial Sensitivity Tests; Pyrimidines; Triazoles; Voriconazole | 2010 |
Voriconazole-micafungin combination therapy for acute lymphoblastic leukemia.
Topics: Antifungal Agents; Antineoplastic Combined Chemotherapy Protocols; Candida tropicalis; Candidiasis; Drug Therapy, Combination; Echinocandins; Follow-Up Studies; Fungemia; Humans; Infant; Lipopeptides; Male; Micafungin; Opportunistic Infections; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Pulmonary Aspergillosis; Pyrimidines; Tomography, X-Ray Computed; Triazoles; Voriconazole | 2010 |
Results from the ARTEMIS DISK Global Antifungal Surveillance Study, 1997 to 2007: a 10.5-year analysis of susceptibilities of Candida Species to fluconazole and voriconazole as determined by CLSI standardized disk diffusion.
Topics: Antifungal Agents; Candida; Candidiasis; Fluconazole; Humans; Microbial Sensitivity Tests; Pyrimidines; Triazoles; Voriconazole | 2010 |
Geographic variation in the frequency of isolation and fluconazole and voriconazole susceptibilities of Candida glabrata: an assessment from the ARTEMIS DISK Global Antifungal Surveillance Program.
Topics: Africa; Americas; Antifungal Agents; Asia; Candida glabrata; Candidiasis; Drug Resistance, Fungal; Europe; Fluconazole; Geography; Humans; Microbial Sensitivity Tests; Middle East; Pyrimidines; Triazoles; Voriconazole | 2010 |
Renal allograft loss due to overwhelming invasive Candida infection.
Topics: Adult; Antifungal Agents; Candidiasis; Drug Therapy, Combination; Female; Fluconazole; Humans; Pyrimidines; Treatment Outcome; Triazoles; Voriconazole | 2010 |
Clinical characteristics and therapeutic analysis of invasive fungal infection in chronic severe hepatitis patients.
Topics: Adult; Aged; Antifungal Agents; Aspergillosis; Candidiasis; Hepatitis, Chronic; Humans; Middle Aged; Mycoses; Pyrimidines; Retrospective Studies; Triazoles; Voriconazole; Young Adult | 2010 |
Successful topical application of caspofungin in the treatment of fungal keratitis refractory to voriconazole.
Topics: Administration, Topical; Antifungal Agents; Candidiasis; Caspofungin; Corneal Ulcer; Drug Resistance, Fungal; Echinocandins; Eye Infections, Fungal; Female; Humans; Lipopeptides; Middle Aged; Pyrimidines; Triazoles; Voriconazole | 2010 |
European guidelines for antifungal management in leukemia and hematopoietic stem cell transplant recipients: summary of the ECIL 3--2009 update.
Topics: Antifungal Agents; Aspergillosis; Candidiasis; Caspofungin; Echinocandins; Hematopoietic Stem Cell Transplantation; Humans; Immunocompromised Host; Leukemia; Lipopeptides; Micafungin; Mycoses; Neutropenia; Opportunistic Infections; Pyrimidines; Triazoles; Voriconazole | 2011 |
Clinical features and outcomes of four patients with invasive fungal sinusitis.
Topics: Aged; Antifungal Agents; Aspergillosis; Biopsy; Blindness; Brain Infarction; Candidiasis; Cavernous Sinus; Combined Modality Therapy; Debridement; Early Diagnosis; Echinocandins; Fatal Outcome; Female; Follow-Up Studies; Humans; Infusions, Intravenous; Lipopeptides; Magnetic Resonance Imaging; Male; Maxillary Sinusitis; Micafungin; Middle Aged; Orbit Evisceration; Orbital Diseases; Postoperative Complications; Pyrimidines; Sphenoid Sinusitis; Tomography, X-Ray Computed; Triazoles; Voriconazole | 2011 |
Wild-type MIC distributions and epidemiological cutoff values for posaconazole and voriconazole and Candida spp. as determined by 24-hour CLSI broth microdilution.
Topics: Antifungal Agents; Candida; Candidiasis; Drug Resistance, Fungal; Humans; Microbial Sensitivity Tests; Pyrimidines; Triazoles; Voriconazole | 2011 |
In vitro evaluation of antibiotic lock technique for the treatment of Candida albicans, C. glabrata, and C. tropicalis biofilms.
Topics: Amphotericin B; Antifungal Agents; Biofilms; Candida albicans; Candida glabrata; Candida tropicalis; Candidiasis; Caspofungin; Catheter-Related Infections; Catheterization, Central Venous; Drug Administration Routes; Echinocandins; Fluconazole; Humans; Itraconazole; Lipopeptides; Microbial Sensitivity Tests; Pyrimidines; Triazoles; Voriconazole | 2010 |
In vitro susceptibility of a large collection of Candida Strains against fluconazole and voriconazole by using the CLSI disk diffusion assay.
Topics: Antifungal Agents; Brazil; Candida; Candidiasis; Disk Diffusion Antimicrobial Tests; Drug Resistance, Fungal; Fluconazole; Humans; Pyrimidines; Triazoles; Voriconazole | 2011 |
Comparison of the broth microdilution (BMD) method of the European Committee on Antimicrobial Susceptibility Testing with the 24-hour CLSI BMD method for testing susceptibility of Candida species to fluconazole, posaconazole, and voriconazole by use of ep
Topics: Antifungal Agents; Candida; Candidiasis; Fluconazole; Humans; Microbial Sensitivity Tests; Pyrimidines; Triazoles; Voriconazole | 2011 |
A case of Candida haemulonii osteitis: clinical features, biochemical characteristics, and antifungal resistance profile.
Topics: Adult; Antifungal Agents; Candida; Candidiasis; Histocytochemistry; Humans; Male; Microbial Sensitivity Tests; Microscopy; Osteitis; Pyrimidines; Triazoles; United States; Vascular Surgical Procedures; Voriconazole | 2011 |
Postoperative endophthalmitis caused by Candida parapsilosis: clinical features and treatment outcomes.
Topics: Aged; Antifungal Agents; Candidiasis; Cataract Extraction; Endophthalmitis; Eye Infections, Fungal; Female; Humans; Intravitreal Injections; Male; Middle Aged; Postoperative Complications; Pseudophakia; Pyrimidines; Retrospective Studies; Treatment Outcome; Triazoles; Visual Acuity; Vitrectomy; Voriconazole | 2011 |
Broth microdilution and time-kill testing of Caspofungin, voriconazole, amphotericin B and their combinations against clinical isolates of Candida krusei.
Topics: Amphotericin B; Antifungal Agents; Candida; Candidiasis; Caspofungin; Echinocandins; Humans; Lipopeptides; Microbial Sensitivity Tests; Microbial Viability; Pyrimidines; Time Factors; Triazoles; Voriconazole | 2012 |
Epidemiology, species distribution, antifungal susceptibility and outcome of nosocomial candidemia in a tertiary care hospital in Italy.
Topics: Aged; Amphotericin B; Antifungal Agents; Candidiasis; Caspofungin; Communicable Disease Control; Cross Infection; Echinocandins; Female; Fluconazole; Hospitals; Humans; Italy; Itraconazole; Lipopeptides; Male; Middle Aged; Pyrimidines; Treatment Outcome; Triazoles; Voriconazole | 2011 |
[Study on in vitro susceptibility of Candida spp. isolated from blood culture].
Topics: Amphotericin B; Antifungal Agents; Blood; Candida; Candidiasis; Caspofungin; Drug Resistance, Fungal; Echinocandins; Fluconazole; Flucytosine; Hospitals; Humans; In Vitro Techniques; Itraconazole; Lipopeptides; Microbial Sensitivity Tests; Pyrimidines; Reproducibility of Results; Risk Factors; Triazoles; Voriconazole | 2012 |
Amino acid substitutions in the Candida albicans sterol Δ5,6-desaturase (Erg3p) confer azole resistance: characterization of two novel mutants with impaired virulence.
Topics: Adult; Amino Acid Substitution; Animals; Antifungal Agents; Candida albicans; Candidiasis; Cell Membrane; Chemoprevention; Drug Resistance, Fungal; Female; Fluconazole; Gas Chromatography-Mass Spectrometry; Gene Expression Profiling; Humans; Mice; Microbial Sensitivity Tests; Middle Aged; Mutant Proteins; Oxidoreductases; Pyrimidines; Sterols; Triazoles; Virulence; Voriconazole | 2012 |
Voriconazole inhibits biofilm formation in different species of the genus Candida.
Topics: Antifungal Agents; Biofilms; Candida; Candidiasis; Humans; Pyrimidines; Staining and Labeling; Tetrazolium Salts; Triazoles; Voriconazole | 2012 |
Postantifungal effect of the combination of caspofungin with voriconazole and amphotericin B against clinical Candida krusei isolates.
Topics: Amphotericin B; Antifungal Agents; Candida; Candidiasis; Caspofungin; Colony Count, Microbial; Drug Synergism; Echinocandins; Humans; Lipopeptides; Microbial Sensitivity Tests; Pyrimidines; Time Factors; Triazoles; Voriconazole | 2013 |
[Fungal infection secondary to treatment of Escherichia coli in a critically ill patient].
Topics: Aged; Anti-Bacterial Agents; Antifungal Agents; Aspergillus; Candida; Candidiasis; Caspofungin; Cross Infection; Drug Resistance, Bacterial; Drug Therapy, Combination; Echinocandins; Escherichia coli; Fungemia; Humans; Lipopeptides; Male; Pyrimidines; Sepsis; Triazoles; Voriconazole | 2012 |
Two clinical isolates of Candida glabrata exhibiting reduced sensitivity to amphotericin B both harbor mutations in ERG2.
Topics: Amino Acid Sequence; Amphotericin B; Antifungal Agents; Azoles; Candida glabrata; Candidiasis; Drug Resistance, Fungal; Fluconazole; Fungal Proteins; Microbial Sensitivity Tests; Molecular Sequence Data; Mutation; Pyrimidines; Saccharomyces cerevisiae; Steroid Isomerases; Sterols; Triazoles; Voriconazole | 2012 |
Voriconazole stability in cement spacers.
Topics: Antifungal Agents; Arthroplasty, Replacement, Hip; Biofilms; Bone Cements; Candida glabrata; Candidiasis; Caspofungin; Device Removal; Dose-Response Relationship, Drug; Drug Implants; Drug Stability; Drug Therapy, Combination; Echinocandins; Hip Prosthesis; Humans; Infusions, Intravenous; Lipopeptides; Male; Middle Aged; Prostheses and Implants; Prosthesis-Related Infections; Pyrimidines; Triazoles; Voriconazole | 2012 |
Voriconazole for Candida endophthalmitis.
Topics: Aged; Antifungal Agents; Candida albicans; Candidiasis; Endophthalmitis; Eye Infections, Fungal; Humans; Intravitreal Injections; Male; Pyrimidines; Tomography, Optical Coherence; Treatment Outcome; Triazoles; Urine; Voriconazole | 2012 |
Antifungal susceptibility to amphotericin B, fluconazole, voriconazole, and flucytosine in Candida bloodstream isolates from 15 tertiary hospitals in Korea.
Topics: Amphotericin B; Antifungal Agents; Candida; Candidiasis; Fluconazole; Flucytosine; Humans; Microbial Sensitivity Tests; Pyrimidines; Republic of Korea; Tertiary Care Centers; Triazoles; Voriconazole | 2012 |
[Endophthalmitis in course of candidosis--a case report].
Topics: Adult; Antifungal Agents; Candidiasis; Endophthalmitis; Eye Infections, Fungal; Humans; Male; Pyrimidines; Treatment Outcome; Triazoles; Vitrectomy; Voriconazole | 2012 |
Non-albicans Candida species in blood stream infections in a tertiary care hospital at New Delhi, India.
Topics: Amphotericin B; Antifungal Agents; Candida; Candidiasis; Cross Infection; Fluconazole; Flucytosine; Humans; Incidence; India; Itraconazole; Microbial Sensitivity Tests; Pyrimidines; Retrospective Studies; Tertiary Care Centers; Triazoles; Voriconazole | 2012 |
Antifungal activity of amphotericin B, fluconazole, and voriconazole in an in vitro model of Candida catheter-related bloodstream infection.
Topics: Amphotericin B; Antifungal Agents; Area Under Curve; Candidiasis; Catheterization; Fluconazole; Half-Life; Microbial Sensitivity Tests; Microscopy, Electron; Pyrimidines; Triazoles; Voriconazole | 2002 |
Successful treatment of Candida glabrata myocarditis with voriconazole.
Topics: Adult; Antifungal Agents; Candida glabrata; Candidiasis; Dose-Response Relationship, Drug; Drug Administration Schedule; Echocardiography, Transesophageal; Follow-Up Studies; Fungemia; Humans; Male; Myocarditis; Pyrimidines; Severity of Illness Index; Tomography, X-Ray Computed; Treatment Outcome; Triazoles; Voriconazole | 2002 |
Activities of fluconazole and voriconazole against 1,586 recent clinical isolates of Candida species determined by Broth microdilution, disk diffusion, and Etest methods: report from the ARTEMIS Global Antifungal Susceptibility Program, 2001.
Topics: Antifungal Agents; Candida; Candidiasis; Drug Resistance, Fungal; Fluconazole; Humans; Microbial Sensitivity Tests; Population Surveillance; Pyrimidines; Triazoles; Voriconazole | 2003 |
Lack of cross-hepatotoxicity between fluconazole and voriconazole.
Topics: Antifungal Agents; Candidiasis; Fluconazole; Humans; Liver; Liver Function Tests; Male; Pyrimidines; Transaminases; Triazoles; Voriconazole | 2003 |
Evaluation of the Etest and disk diffusion methods for determining susceptibilities of 235 bloodstream isolates of Candida glabrata to fluconazole and voriconazole.
Topics: Agar; Antifungal Agents; Candida glabrata; Candidiasis; Culture Media; Fluconazole; Fungemia; Humans; Microbial Sensitivity Tests; Pyrimidines; Quality Control; Triazoles; Voriconazole | 2003 |
Trends in frequency and in vitro susceptibilities to antifungal agents, including voriconazole and anidulafungin, of Candida bloodstream isolates. Results from a six-year study (1996-2001).
Topics: Anidulafungin; Antifungal Agents; Candida; Candidiasis; Drug Resistance, Fungal; Echinocandins; Female; Fungemia; Hospitals, University; Humans; Male; Microbial Sensitivity Tests; Peptides, Cyclic; Pyrimidines; Retrospective Studies; Sensitivity and Specificity; Spain; Triazoles; Voriconazole | 2003 |
[Update on voriconazole].
Topics: Adult; Age Factors; AIDS-Related Opportunistic Infections; Antifungal Agents; Aspergillosis; Candidiasis; Child; Humans; Mycoses; Pyrimidines; Randomized Controlled Trials as Topic; Triazoles; Voriconazole | 2003 |
[In vitro activity of fluconazole, voriconazole and posaconazole against Candida spp].
Topics: Antifungal Agents; Candida; Candidiasis; Drug Resistance, Fungal; Fluconazole; Humans; Microbial Sensitivity Tests; Pyrimidines; Species Specificity; Triazoles; Voriconazole | 2003 |
In vivo pharmacokinetics and pharmacodynamics of a new triazole, voriconazole, in a murine candidiasis model.
Topics: Administration, Oral; Animals; Antifungal Agents; Area Under Curve; Candida albicans; Candidiasis; Colony Count, Microbial; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Resistance, Fungal; Female; Fluconazole; Kidney; Mice; Microbial Sensitivity Tests; Neutropenia; Pyrimidines; Triazoles; Voriconazole | 2003 |
Serum voriconazole levels following administration via percutaneous jejunostomy tube.
Topics: Aged; Candida glabrata; Candidiasis; Drug Administration Routes; Humans; Jejunostomy; Male; Pyrimidines; Triazoles; Voriconazole | 2003 |
Voriconazole--superior in antimycotic treatment.
Topics: Antifungal Agents; Candida; Candidiasis; Clinical Trials as Topic; Female; Humans; Male; Pyrimidines; Sensitivity and Specificity; Treatment Outcome; Triazoles; Voriconazole | 2003 |
Voriconazole salvage treatment of invasive candidiasis.
Topics: Adolescent; Adult; Aged; Antifungal Agents; Candida; Candidiasis; Child; Child, Preschool; Cohort Studies; Confidence Intervals; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Follow-Up Studies; Fungemia; Humans; Male; Middle Aged; Prospective Studies; Pyrimidines; Risk Assessment; Salvage Therapy; Severity of Illness Index; Treatment Outcome; Triazoles; Voriconazole | 2003 |
Comparison of the susceptibilities of Candida spp. to fluconazole and voriconazole in a 4-year global evaluation using disk diffusion.
Topics: Antifungal Agents; Candida; Candidiasis; Diffusion; Fluconazole; Humans; Microbial Sensitivity Tests; Pyrimidines; Triazoles; Voriconazole | 2003 |
National surveillance of species distribution in blood isolates of Candida species in Japan and their susceptibility to six antifungal agents including voriconazole and micafungin.
Topics: Amphotericin B; Antifungal Agents; Candida; Candidiasis; Echinocandins; Flucytosine; Humans; Itraconazole; Japan; Lipopeptides; Lipoproteins; Micafungin; Microbial Sensitivity Tests; Peptides, Cyclic; Pyrimidines; Triazoles; Voriconazole | 2004 |
Comparison of two microdilution methods for testing susceptibility of Candida spp. to voriconazole.
Topics: Antifungal Agents; Candida; Candidiasis; Colorimetry; Microbial Sensitivity Tests; Mycology; Pyrimidines; Sensitivity and Specificity; Triazoles; Voriconazole | 2004 |
[symbol: see text]Caspofungin and [symbol: see text]voriconazole for fungal infections.
Topics: Antifungal Agents; Aspergillosis; Candidiasis; Caspofungin; Echinocandins; Humans; Lipopeptides; Mycoses; Peptides; Peptides, Cyclic; Pyrimidines; Randomized Controlled Trials as Topic; Triazoles; Voriconazole | 2004 |
Secondary antifungal prophylaxis with voriconazole to adhere to scheduled treatment in leukemic patients and stem cell transplant recipients.
Topics: Adolescent; Adult; Antifungal Agents; Aspergillosis; Aspergillus; Candida; Candidiasis; Female; Graft vs Host Disease; Humans; Leukemia; Male; Middle Aged; Prognosis; Prospective Studies; Pyrimidines; Recurrence; Risk; Stem Cell Transplantation; Transplantation, Homologous; Triazoles; Voriconazole | 2004 |
Use of voriconazole in candida retinitis.
Topics: Adult; Antifungal Agents; Candidiasis; Eye Infections, Fungal; Fatal Outcome; Female; Humans; Opportunistic Infections; Pyrimidines; Triazoles; Voriconazole | 2005 |
In vitro activities of voriconazole (UK-109, 496), fluconazole, itraconazole and amphotericin B against 132 non-albicans bloodstream yeast isolates (CANARI study).
Topics: Amphotericin B; Antifungal Agents; Candida; Candidiasis; Fluconazole; Humans; Itraconazole; Microbial Sensitivity Tests; Pyrimidines; Saccharomyces cerevisiae; Triazoles; Voriconazole | 2004 |
Alternatives to amphotericin B for Candida rugosa infection.
Topics: Amphotericin B; Animals; Antifungal Agents; Candidiasis; Colony Count, Microbial; Fluconazole; Kidney; Male; Mice; Mice, Inbred ICR; Microbial Sensitivity Tests; Neutropenia; Organ Size; Pyrimidines; Spleen; Survival Analysis; Triazoles; Voriconazole | 2004 |
Pfizer's Vfend as effective in treating candidemia as two-drug standard of care according to study.
Topics: Amphotericin B; Antifungal Agents; Candida; Candidiasis; Fungemia; Humans; Pyrimidines; Randomized Controlled Trials as Topic; Treatment Outcome; Triazoles; Voriconazole | 2004 |
In vitro activity of voriconazole and other antifungal agents against clinical isolates of Candida glabrata and Candida krusei.
Topics: Antifungal Agents; Candida; Candida glabrata; Candidiasis; Drug Resistance, Fungal; Humans; In Vitro Techniques; Italy; Microbial Sensitivity Tests; Pyrimidines; Sampling Studies; Sensitivity and Specificity; Triazoles; Voriconazole | 2004 |
Influence of voriconazole and fluconazole on reconstituted multilayered oesophageal epithelium infected by Candida albicans.
Topics: Antifungal Agents; Candida albicans; Candidiasis; Cell Line, Tumor; Epithelial Cells; Esophagitis; Esophagus; Fluconazole; Humans; Microbial Sensitivity Tests; Models, Biological; Pyrimidines; Triazoles; Voriconazole | 2004 |
In vitro activity of voriconazole against Candida species isolated in Taiwan.
Topics: Antifungal Agents; Candida; Candidiasis; Drug Resistance, Fungal; Fluconazole; Humans; Microbial Sensitivity Tests; Pyrimidines; Taiwan; Triazoles; Voriconazole | 2004 |
Breakthrough fungal infections in stem cell transplant recipients receiving voriconazole.
Topics: Adult; Aspergillosis; Aspergillus; Candida glabrata; Candidiasis; Child; Drug Resistance, Fungal; Female; Fungemia; Fungi; Humans; Immunocompromised Host; Male; Microbial Sensitivity Tests; Middle Aged; Pyrimidines; Retrospective Studies; Stem Cell Transplantation; Triazoles; Voriconazole; Zygomycosis | 2004 |
Clinical evaluation of the Sensititre YeastOne colorimetric antifungal plate for antifungal susceptibility testing of the new triazoles voriconazole, posaconazole, and ravuconazole.
Topics: Antifungal Agents; Candida; Candidiasis; Humans; Microbial Sensitivity Tests; Pyrimidines; Reagent Kits, Diagnostic; Thiazoles; Triazoles; Voriconazole | 2004 |
Altered susceptibility of Candida glabrata bloodstream isolates to triazoles at clinically relevant pH values: comparison of the NCCLS M27-A2, Sensititre YeastOne, and Etest methods.
Topics: Antifungal Agents; Candida glabrata; Candidiasis; Culture Media; Fluconazole; Hydrogen-Ion Concentration; Itraconazole; Microbial Sensitivity Tests; Pyrimidines; Triazoles; Voriconazole | 2004 |
In vitro pharmacodynamic characteristics of amphotericin B, caspofungin, fluconazole, and voriconazole against bloodstream isolates of infrequent Candida species from patients with hematologic malignancies.
Topics: Amphotericin B; Antifungal Agents; Candida; Candidiasis; Caspofungin; Colony Count, Microbial; Echinocandins; Fluconazole; Hematologic Neoplasms; Humans; Kinetics; Lipopeptides; Microbial Sensitivity Tests; Models, Biological; Peptides, Cyclic; Pyrimidines; Triazoles; Voriconazole | 2004 |
[Efficiency of voriconazole in fungal keratitis caused by candida albicans].
Topics: Aged; Antifungal Agents; Candidiasis; Female; Humans; Keratitis; Pyrimidines; Triazoles; Voriconazole | 2004 |
Combined use of sirolimus and voriconazole in renal transplantation: a report of two cases.
Topics: Adult; Antifungal Agents; Aspergillosis; Aspergillus fumigatus; Candidiasis; Female; Humans; Immunosuppressive Agents; Kidney Transplantation; Lung Diseases, Fungal; Male; Middle Aged; Postoperative Complications; Pyrimidines; Sirolimus; Triazoles; Voriconazole | 2004 |
Candida infection of the subacromial bursa. A case report.
Topics: Acromion; Aged; Anti-Inflammatory Agents; Antifungal Agents; Bupivacaine; Bursa, Synovial; Bursitis; Candidiasis; Decompression, Surgical; Humans; Injections, Intra-Articular; Lidocaine; Male; Methylprednisolone; Methylprednisolone Acetate; Pyrimidines; Shoulder Impingement Syndrome; Triazoles; Voriconazole | 2005 |
Management of endogenous fungal endophthalmitis with voriconazole and caspofungin.
Topics: Administration, Oral; Adult; Aged; Antifungal Agents; Aqueous Humor; Biological Availability; Candidiasis; Caspofungin; Chromatography, High Pressure Liquid; Echinocandins; Endophthalmitis; Eye Infections, Fungal; Female; Fungemia; Humans; Infusions, Intravenous; Injections; Lipopeptides; Male; Middle Aged; Peptides, Cyclic; Pyrimidines; Retrospective Studies; Triazoles; Vitreous Body; Voriconazole | 2005 |
[Drugs used in prophylaxis and treatment of fungal infections in immunosuppressed children].
Topics: Antifungal Agents; Aspergillosis; Candidiasis; Caspofungin; Child; Drug Resistance, Fungal; Echinocandins; Humans; Immunocompromised Host; Lipopeptides; Mycoses; Neoplasms; Peptides, Cyclic; Pyrimidines; Risk Factors; Triazoles; Voriconazole | 2004 |
Infection of a total knee prosthesis by Candida glabrata: a case report.
Topics: Aged; Antifungal Agents; Arthroplasty, Replacement, Knee; Candida glabrata; Candidiasis; Female; Humans; Pyrimidines; Surgical Wound Infection; Treatment Outcome; Triazoles; Voriconazole | 2005 |
Intravenous voriconazole therapy in a preterm infant.
Topics: Amphotericin B; Antifungal Agents; Candidiasis; Humans; Infant, Newborn; Infant, Premature; Infusions, Intravenous; Pyrimidines; Triazoles; Voriconazole | 2005 |
Treatment of candida chorioretinitis with voriconazole.
Topics: Antifungal Agents; Candidiasis; Chorioretinitis; Eye Infections, Fungal; Female; Fungemia; Humans; Middle Aged; Pyrimidines; Triazoles; Voriconazole | 2005 |
[Treatment of invasive fungal infections with voriconazole. Evaluation of experience with compassionate use of voriconazole in Spain].
Topics: Adolescent; Adult; Aged; Amphotericin B; Antifungal Agents; Aspergillosis; Candidiasis; Child; Child, Preschool; Drug Resistance, Fungal; Female; Humans; Male; Middle Aged; Mycoses; Pyrimidines; Retrospective Studies; Spain; Treatment Outcome; Triazoles; Voriconazole | 2005 |
Comparison of visual 24-hour and spectrophotometric 48-hour MICs to CLSI reference microdilution MICs of fluconazole, itraconazole, posaconazole, and voriconazole for Candida spp.: a collaborative study.
Topics: Antifungal Agents; Candida; Candidiasis; Drug Resistance, Fungal; Fluconazole; Humans; Itraconazole; Microbial Sensitivity Tests; Pyrimidines; Reference Standards; Reproducibility of Results; Spectrophotometry; Triazoles; Voriconazole | 2005 |
Species distribution and antifungal susceptibility of Candida bloodstream isolates in a tertiary medical center in Israel.
Topics: Academic Medical Centers; Amphotericin B; Antifungal Agents; Candida; Candida albicans; Candida glabrata; Candida tropicalis; Candidiasis; Drug Resistance, Fungal; Fluconazole; Fungemia; Humans; Israel; Itraconazole; Pyrimidines; Species Specificity; Triazoles; Voriconazole | 2005 |
Emergence of Candida albicans fungemia during voriconazole therapy.
Topics: Adult; Antifungal Agents; Candida albicans; Candidiasis; Drug Resistance, Fungal; Fatal Outcome; Female; Fungemia; Humans; Microbial Sensitivity Tests; Pyrimidines; Triazoles; Voriconazole | 2005 |
Septic Candida krusei thrombophlebitis of inferior vena cava with persistent fungemia successfully treated by new antifungal agents.
Topics: Adult; Antifungal Agents; Candida; Candidiasis; Caspofungin; Echinocandins; Female; Fungemia; Humans; Intensive Care Units; Lipopeptides; Peptides, Cyclic; Pyrimidines; Thrombophlebitis; Triazoles; Vena Cava, Inferior; Voriconazole | 2005 |
Voriconazole.
Topics: Antifungal Agents; Aspergillosis; Candidiasis; Drug Interactions; Humans; Pyrimidines; Triazoles; Voriconazole | 2005 |
Breakthrough fungemia caused by fluconazole-resistant Candida albicans with decreased susceptibility to voriconazole in patients with hematologic malignancies.
Topics: Candida albicans; Candidiasis; Drug Resistance; Fluconazole; Fungemia; Hematologic Neoplasms; Humans; Pyrimidines; Retrospective Studies; Triazoles; Voriconazole | 2006 |
[Voriconazole at Saint Louis Hospital (Paris): Analysis of two-years of compassionate use].
Topics: Acute Disease; Antifungal Agents; Aspergillosis; Candidiasis; Cohort Studies; Fusarium; Hematopoietic Stem Cell Transplantation; Humans; Immunocompromised Host; Leukemia; Mycoses; Pyrimidines; Retrospective Studies; Time Factors; Treatment Outcome; Triazoles; Voriconazole | 2006 |
Candidaemia secondary to intravascular catheter colonisation?
Topics: Amphotericin B; Antifungal Agents; Candidiasis; Catheterization, Central Venous; Equipment Contamination; Humans; Pyrimidines; Triazoles; Voriconazole | 2006 |
Successful treatment of Candida parapsilosis mural endocarditis with combined caspofungin and voriconazole.
Topics: Antifungal Agents; Candidiasis; Caspofungin; Drug Therapy, Combination; Echinocandins; Endocarditis; Female; Humans; Lipopeptides; Middle Aged; Peptides, Cyclic; Pyrimidines; Treatment Outcome; Triazoles; Voriconazole | 2006 |
Clinical significance of azole antifungal drug cross-resistance in Candida glabrata.
Topics: Adult; Antifungal Agents; Candida glabrata; Candidiasis; Child; Drug Resistance, Fungal; Fluconazole; Fungemia; Hematopoietic Stem Cell Transplantation; Humans; Itraconazole; Middle Aged; Pyrimidines; Triazoles; Voriconazole | 2006 |
Spondylodiscitis caused by Candida krusei: case report and susceptibility patterns.
Topics: Amphotericin B; Antifungal Agents; Candida; Candidiasis; Caspofungin; Discitis; Drug Resistance, Fungal; Echinocandins; Humans; Lipopeptides; Magnetic Resonance Imaging; Male; Microbial Sensitivity Tests; Middle Aged; Peptides, Cyclic; Pyrimidines; Triazoles; Voriconazole | 2006 |
In vitro activities of posaconazole, fluconazole, itraconazole, voriconazole, and amphotericin B against a large collection of clinically important molds and yeasts.
Topics: Amphotericin B; Antifungal Agents; Aspergillosis; Aspergillus; Candida; Candidiasis; Cryptococcosis; Cryptococcus; Drug Resistance, Fungal; Fluconazole; Fungi; Humans; In Vitro Techniques; Itraconazole; Microbial Sensitivity Tests; Mycoses; Pyrimidines; Triazoles; Voriconazole | 2006 |
Antifungal effect of voriconazole on intracellular Candida glabrata, Candida krusei and Candida parapsilosis in human monocyte-derived macrophages.
Topics: Antifungal Agents; Candida; Candidiasis; Colony Count, Microbial; Dose-Response Relationship, Drug; Drug Resistance, Fungal; Humans; Macrophages; Pyrimidines; Triazoles; Voriconazole | 2006 |
A case of pulmonary aspergillosis with lack of response to caspofungin.
Topics: Acute Disease; Antifungal Agents; Antineoplastic Combined Chemotherapy Protocols; Aspergillosis; Bone Marrow Diseases; Candidiasis; Caspofungin; Combined Modality Therapy; Contraindications; Echinocandins; Fatal Outcome; Female; Hematopoietic Stem Cell Transplantation; Hepatitis; Humans; Immunocompromised Host; Immunosuppressive Agents; Leukemia, Myeloid; Lipopeptides; Lung Diseases, Fungal; Middle Aged; Peptides, Cyclic; Postoperative Complications; Pyrimidines; Splenic Diseases; Triazoles; Voriconazole | 2006 |
Use of the BIOMIC Video System to evaluate the susceptibility of clinical yeast isolates to fluconazole and voriconazole by a disk diffusion method.
Topics: Candida; Candidiasis; Fluconazole; Humans; Image Processing, Computer-Assisted; Microbial Sensitivity Tests; Microscopy, Video; Pyrimidines; Triazoles; Voriconazole | 2006 |
[Candida albicans induced spondylodiscitis of the cervical spine of a polytraumatized patient].
Topics: Adult; Antifungal Agents; Candidiasis; Cervical Vertebrae; Combined Modality Therapy; Discitis; Epidural Abscess; Fluconazole; Follow-Up Studies; Head Movements; Humans; Lung Diseases, Fungal; Male; Multiple Trauma; Pyrimidines; Radiography; Triazoles; Voriconazole | 2006 |
Severe Candida albicans panophthalmitis treated with all available and potentially effective antifungal drugs: fluconazole, liposomal amphotericin B, caspofungin, and voriconazole.
Topics: Amphotericin B; Antifungal Agents; Candida albicans; Candidiasis; Caspofungin; Echinocandins; Fluconazole; Humans; Lipopeptides; Male; Middle Aged; Panophthalmitis; Peptides, Cyclic; Pyrimidines; Triazoles; Voriconazole | 2006 |
Candida guilliermondii, an opportunistic fungal pathogen with decreased susceptibility to fluconazole: geographic and temporal trends from the ARTEMIS DISK antifungal surveillance program.
Topics: Candida; Candidiasis; Caspofungin; Drug Resistance, Fungal; Echinocandins; Fluconazole; Global Health; Humans; Lipopeptides; Peptides, Cyclic; Population Surveillance; Pyrimidines; Triazoles; Voriconazole | 2006 |
Candida rugosa, an emerging fungal pathogen with resistance to azoles: geographic and temporal trends from the ARTEMIS DISK antifungal surveillance program.
Topics: Antifungal Agents; Candida; Candidiasis; Drug Resistance, Fungal; Fluconazole; Global Health; Humans; Population Surveillance; Pyrimidines; Triazoles; Voriconazole | 2006 |
Echinocandins for candidemia.
Topics: Antifungal Agents; Candidiasis; Fluconazole; Fungemia; Humans; Pyrimidines; Triazoles; Voriconazole | 2006 |
In vitro activities of voriconazole and five licensed antifungal agents against Candida dubliniensis: comparison of CLSI M27-A2, Sensititre YeastOne, disk diffusion, and Etest methods.
Topics: Antifungal Agents; Candida; Candidiasis; Colorimetry; Indicator Dilution Techniques; Microbial Sensitivity Tests; Mycological Typing Techniques; Pyrimidines; Reference Standards; Triazoles; Voriconazole; Yeasts | 2006 |
Voriconazole-induced pseudoporphyria.
Topics: Antifungal Agents; Candidiasis; Drug Eruptions; Female; Humans; Middle Aged; Porphyria, Acute Intermittent; Pyrimidines; Triazoles; Voriconazole | 2007 |
Caspofungin for the treatment of azole resistant candidemia in a premature infant.
Topics: Antifungal Agents; Candida albicans; Candidiasis; Caspofungin; Drug Resistance, Microbial; Echinocandins; Humans; Hypercalcemia; Infant, Newborn; Infant, Premature; Infant, Premature, Diseases; Lipopeptides; Male; Peptides, Cyclic; Pyrimidines; Triazoles; Voriconazole | 2007 |
Species distribution and antifungal susceptibility patterns of Candida spp. bloodstream isolates from a Brazilian tertiary care hospital.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Amphotericin B; Antifungal Agents; Brazil; Candida; Candidiasis; Drug Resistance, Fungal; Female; Fluconazole; Hospitals; Humans; Intensive Care Units; Itraconazole; Male; Microbial Sensitivity Tests; Middle Aged; Pyrimidines; Risk Factors; Triazoles; Voriconazole | 2007 |
The effects of caspofungin and voriconazole in experimental Candida endophthalmitis.
Topics: Amphotericin B; Animals; Antifungal Agents; Candida albicans; Candidiasis; Caspofungin; Colony Count, Microbial; Cornea; Disease Models, Animal; Echinocandins; Endophthalmitis; Eye Infections, Fungal; Itraconazole; Lipopeptides; Peptides, Cyclic; Pyrimidines; Rabbits; Triazoles; Voriconazole | 2007 |
Acquired resistance to echinocandins in Candida albicans: case report and review.
Topics: Adult; Amino Acid Sequence; Amino Acid Substitution; Amphotericin B; Antifungal Agents; Candida albicans; Candidiasis; Caspofungin; Drug Resistance, Fungal; Echinocandins; Fluconazole; Genotype; HIV Infections; HIV-1; Humans; Lipopeptides; Lipoproteins; Male; Micafungin; Microbial Sensitivity Tests; Molecular Sequence Data; Peptides, Cyclic; Pyrimidines; Treatment Failure; Triazoles; Voriconazole | 2007 |
Does one voriconazole breakpoint suit all Candida species?
Topics: Antifungal Agents; Candida; Candidiasis; Humans; Microbial Sensitivity Tests; Pyrimidines; Species Specificity; Triazoles; Voriconazole | 2007 |
Breakthrough fungal infections after allogeneic hematopoietic stem cell transplantation in patients on prophylactic voriconazole.
Topics: Antifungal Agents; Aspergillosis; Candidiasis; Data Collection; Drug Evaluation; Female; Hematopoietic Stem Cell Transplantation; Humans; Male; Mycoses; Premedication; Pyrimidines; Transplantation, Homologous; Triazoles; Voriconazole; Zygomycosis | 2007 |
Voriconazole: a broad spectrum triazole for the treatment of serious and invasive fungal infections.
Topics: Administration, Oral; Antifungal Agents; Aspergillosis; Candidiasis; Drug Evaluation; Drug Resistance, Fungal; Fluconazole; Humans; Injections, Intravenous; Molecular Structure; Pyrimidines; Treatment Outcome; Triazoles; Voriconazole | 2006 |
In vitro activities of voriconazole as a triazole derivative and caspofungin as an echinocandin were compared with those of some antifungal agents against Candida species isolated from clinical specimens.
Topics: Antifungal Agents; Candida; Candidiasis; Caspofungin; Drug Resistance, Fungal; Echinocandins; Humans; Lipopeptides; Microbial Sensitivity Tests; Pyrimidines; Sputum; Triazoles; Voriconazole | 2007 |
Triple antifungal therapy for severe systemic candidiasis allowed performance of allogeneic stem cell transplantation.
Topics: Adult; Amphotericin B; Antifungal Agents; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Candidiasis; Caspofungin; Drug Therapy, Combination; Echinocandins; Hematopoietic Stem Cell Transplantation; Humans; Immunocompromised Host; Leukemia-Lymphoma, Adult T-Cell; Lipopeptides; Liposomes; Male; Peptides, Cyclic; Pyrimidines; Transplantation Conditioning; Transplantation, Homologous; Triazoles; Voriconazole | 2007 |
Species distribution and susceptibility to azole antifungals of Candida bloodstream isolates from eight university hospitals in Korea.
Topics: Antifungal Agents; Azoles; Bacteremia; Candida; Candidiasis; Drug Resistance, Fungal; Fluconazole; Hospitals, University; Humans; Itraconazole; Microbial Sensitivity Tests; Population Surveillance; Pyrimidines; Triazoles; Voriconazole | 2007 |
Activities of fluconazole and voriconazole against bloodstream isolates of Candida glabrata and Candida krusei: a 14-year study in a Spanish tertiary medical centre.
Topics: Antifungal Agents; Candida; Candidiasis; Drug Resistance, Fungal; Fluconazole; Fungemia; Hospitals; Humans; Microbial Sensitivity Tests; Pyrimidines; Spain; Triazoles; Voriconazole | 2008 |
Managing Candida endophthalmitis (Recurrent Candida albicans endophthalmitis in an immunocompromised host. Vol. 42[1]).
Topics: Amphotericin B; Antifungal Agents; Candidiasis; Endophthalmitis; Eye Infections, Fungal; Humans; Immunocompromised Host; Postoperative Complications; Pyrimidines; Recurrence; Triazoles; Voriconazole | 2007 |
Selection of a surrogate agent (fluconazole or voriconazole) for initial susceptibility testing of posaconazole against Candida spp.: results from a global antifungal surveillance program.
Topics: Antifungal Agents; Biomarkers; Candida; Candidiasis; Fluconazole; Humans; Microbial Sensitivity Tests; Pyrimidines; Regression Analysis; Triazoles; Voriconazole | 2008 |
Voriconazole therapeutic drug monitoring in patients with invasive mycoses improves efficacy and safety outcomes.
Topics: Adult; Aged; Antifungal Agents; Aspergillosis; Candidiasis; Chromatography, High Pressure Liquid; Drug Monitoring; Female; Humans; Male; Middle Aged; Mycoses; Pyrimidines; Retrospective Studies; Triazoles; Voriconazole | 2008 |
High-dose voriconazole in a critically ill pediatric patient with neuroblastoma.
Topics: Antifungal Agents; Candidiasis; Child, Preschool; Critical Illness; Humans; Lung Diseases; Male; Neuroblastoma; Pyrimidines; Triazoles; Voriconazole | 2008 |
Geographic and temporal trends in isolation and antifungal susceptibility of Candida parapsilosis: a global assessment from the ARTEMIS DISK Antifungal Surveillance Program, 2001 to 2005.
Topics: Africa; Antifungal Agents; Asia; Candida; Candidiasis; Drug Resistance, Fungal; Echinocandins; Europe; Fluconazole; Fungemia; Global Health; Humans; Latin America; Microbial Sensitivity Tests; Middle East; North America; Population Surveillance; Pyrimidines; Triazoles; Voriconazole | 2008 |
Bile aspiration for diagnosis of Candida glabrata cholecystitis.
Topics: Acalculous Cholecystitis; Aged; Animals; Antifungal Agents; Bile; Biopsy, Needle; Candida glabrata; Candidiasis; Female; Humans; Pyrimidines; Triazoles; Voriconazole | 2008 |
Voriconazole in newborns.
Topics: Antifungal Agents; Aspergillosis; Aspergillus; Candida; Candidiasis; Critical Illness; Humans; Infant, Newborn; Pyrimidines; Triazoles; Voriconazole | 2008 |
Activities and ultrastructural effects of antifungal combinations against simulated Candida endocardial vegetations.
Topics: Antifungal Agents; Candida; Candida albicans; Candida glabrata; Candida tropicalis; Candidiasis; Drug Resistance, Fungal; Drug Therapy, Combination; Echinocandins; Endocarditis; Flucytosine; Humans; In Vitro Techniques; Lipopeptides; Lipoproteins; Micafungin; Microbial Sensitivity Tests; Microscopy, Electron, Scanning; Models, Biological; Pyrimidines; Triazoles; Voriconazole | 2008 |
[Short communication: In vitro activity of amphotericin B with fluconazole or voriconazole combinations against Candida albicans isolates].
Topics: Amphotericin B; Antifungal Agents; Candida albicans; Candidiasis; Drug Interactions; Fluconazole; Humans; Microbial Sensitivity Tests; Pyrimidines; Reproducibility of Results; Triazoles; Voriconazole | 2008 |
In vitro activities of voriconazole (UK-109,496) and four other antifungal agents against 394 clinical isolates of Candida spp.
Topics: Amphotericin B; Antifungal Agents; Candida; Candidiasis; Fluconazole; Flucytosine; Humans; Itraconazole; Microbial Sensitivity Tests; Pyrimidines; Triazoles; Voriconazole | 1998 |
In vitro susceptibilities of Candida bloodstream isolates to the new triazole antifungal agents BMS-207147, Sch 56592, and voriconazole.
Topics: Antifungal Agents; Candida; Candidiasis; Humans; Microbial Sensitivity Tests; Pyrimidines; Thiazoles; Triazoles; Voriconazole | 1998 |
In vitro susceptibilities of Candida dubliniensis isolates tested against the new triazole and echinocandin antifungal agents.
Topics: AIDS-Related Opportunistic Infections; Amphotericin B; Anti-Bacterial Agents; Antifungal Agents; Candida; Candidiasis; Caspofungin; Echinocandins; Fluconazole; Flucytosine; Humans; Itraconazole; Lipopeptides; Microbial Sensitivity Tests; Peptides; Peptides, Cyclic; Pyrimidines; Thiazoles; Triazoles; Voriconazole | 1999 |
Antifungal activity of voriconazole (UK-109,496), fluconazole and amphotericin B against hematogenous Candida krusei infection in neutropenic guinea pig model.
Topics: Amphotericin B; Animals; Antifungal Agents; Candida; Candidiasis; Disease Models, Animal; Drug Resistance, Microbial; Fluconazole; Guinea Pigs; Male; Neutropenia; Pyrimidines; Random Allocation; Triazoles; Voriconazole | 1999 |
[Therapy of deep seated mycoses--Timing of administration and selection of antifungal agents].
Topics: Amphotericin B; Animals; Antifungal Agents; Aspergillosis; Candidiasis; Fluconazole; Humans; Immunocompromised Host; Itraconazole; Mycoses; Nystatin; Pyrimidines; Triazoles; Voriconazole | 2000 |
In vitro activity of fluconazole and voriconazole against isolates of Candida albicans from patients with haematological malignancies.
Topics: Antifungal Agents; Candida albicans; Candidiasis; Fluconazole; Hematologic Neoplasms; Humans; Microbial Sensitivity Tests; Pyrimidines; Triazoles; Voriconazole | 2000 |
Voriconazole: a new triazole antifungal.
Topics: Antifungal Agents; Aspergillosis; Aspergillus; Candida; Candidiasis; Controlled Clinical Trials as Topic; Drug Interactions; Drug Resistance, Microbial; Humans; Pyrimidines; Retrospective Studies; Tissue Distribution; Triazoles; Voriconazole | 2000 |
Evaluation of the Etest method for determining voriconazole susceptibilities of 312 clinical isolates of Candida species by using three different agar media.
Topics: Agar; Antifungal Agents; Candida; Candida albicans; Candidiasis; Culture Media; Humans; Microbial Sensitivity Tests; Pyrimidines; Triazoles; Voriconazole | 2000 |
Susceptibility testing of voriconazole, fluconazole, itraconazole and amphotericin B against yeast isolates in a Turkish University Hospital and effect of time of reading.
Topics: Amphotericin B; Antifungal Agents; Candida; Candidiasis; Fluconazole; Hospitals, University; Humans; Itraconazole; Microbial Sensitivity Tests; Mycoses; Pyrimidines; Reference Standards; Time Factors; Triazoles; Trichosporon; Turkey; Voriconazole | 2000 |
Synergism of voriconazole and terbinafine against Candida albicans isolates from human immunodeficiency virus-infected patients with oropharyngeal candidiasis.
Topics: AIDS-Related Opportunistic Infections; Antifungal Agents; Candida albicans; Candidiasis; Drug Resistance, Microbial; Drug Synergism; HIV Infections; Humans; Microbial Sensitivity Tests; Naphthalenes; Pharyngitis; Pyrimidines; Terbinafine; Triazoles; Voriconazole | 2001 |
Fluconazole and voriconazole multidisk testing of Candida species for disk test calibration and MIC estimation.
Topics: Antifungal Agents; Calibration; Candida; Candidiasis; Fluconazole; Humans; Microbial Sensitivity Tests; Pyrimidines; Triazoles; Voriconazole | 2001 |
[Antifungal susceptibility testing in chronically recurrent vaginal candidosis as basis for effective therapy].
Topics: Amphotericin B; Antifungal Agents; Candida; Candidiasis; Chronic Disease; Ciclopirox; Female; Fluconazole; Flucytosine; Humans; Itraconazole; Microbial Sensitivity Tests; Naphthalenes; Pyridones; Pyrimidines; Terbinafine; Triazoles; Vaginitis; Voriconazole | 2000 |
International surveillance of bloodstream infections due to Candida species: frequency of occurrence and in vitro susceptibilities to fluconazole, ravuconazole, and voriconazole of isolates collected from 1997 through 1999 in the SENTRY antimicrobial surv
Topics: Antifungal Agents; Candida; Candidiasis; Europe; Fluconazole; Fungemia; Humans; Latin America; North America; Pyrimidines; Sentinel Surveillance; Thiazoles; Triazoles; Voriconazole | 2001 |
Voriconazole and fluconazole susceptibility of Candida isolates.
Topics: Antifungal Agents; Candida; Candidiasis; Colony Count, Microbial; Drug Resistance, Fungal; Fluconazole; Humans; Microbial Sensitivity Tests; Pyrimidines; Treatment Outcome; Triazoles; Voriconazole | 2002 |
In vitro activities of ravuconazole and voriconazole compared with those of four approved systemic antifungal agents against 6,970 clinical isolates of Candida spp.
Topics: Antifungal Agents; Candida; Candidiasis; Drug Resistance, Microbial; Humans; Microbial Sensitivity Tests; Pyrimidines; Thiazoles; Triazoles; Voriconazole | 2002 |
In vitro activity of three new triazoles and one echinocandin against Candida bloodstream isolates from cancer patients.
Topics: Antifungal Agents; Blood; Candida; Candidiasis; Echinocandins; Humans; In Vitro Techniques; Lipopeptides; Lipoproteins; Micafungin; Microbial Sensitivity Tests; Neoplasms; Peptides, Cyclic; Pyrimidines; Thiazoles; Triazoles; Voriconazole | 2002 |